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CHAPTER I 
 
INTRODUCTION 
 
Identifying the in vivo targets of bacterial toxins using the zebrafish embryo 
as a model.  (Elaine E. Hamm, and Jimmy D. Ballard).  Future Microbiology. 
(2007)  2:1 85-92. 
 
During infection and disease, bacterial pathogens alter host cell physiology.  This 
alteration of the host allows the pathogen to establish niches for growth, avoid 
clearance by the immune system, and obtain nutrients.  As a consequence, 
pathogens cause tissue damage that can account for the majority of disease 
symptoms.  For many pathogens, this damage to the host can be attributed to the 
production of virulence factors such as soluble exotoxins, which target and often 
kill cells.  Thus, studying the virulence factors that alter normal physiological 
processes in the host and identifying their targets can provide important insight 
into infectious diseases.  In this dissertation, we discuss important gaps in our 
knowledge of the bacterial toxins and describe a new model for addressing one 
fundamental problem, the elucidation of in vivo targets of these toxins. 
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Bacterial toxins are soluble proteins produced by a variety of pathogens.  As major 
virulence factors, the establishment and progression of bacterial infections often 
rely on the production of bacterial toxins.  Indeed, isogenic strains with one or 
more toxin genes interrupted are often substantially reduced in virulence (34, 72, 
158); in cases such as bacterial neurotoxins and diphtheria toxin, the major signs 
and symptoms of disease can be recapitulated by the toxin alone (207).  
Furthermore, vaccines against diphtheria toxin (70) and tetanus toxin (167) can 
completely prevent disease initiated by infection with the whole organism.  For 
these reasons, toxins have been studied extensively at the atomic, molecular, and 
cellular levels in order to gain insight into how bacterial pathogens destroy target 
cells.   
 
Bacterial toxins are roughly divided into two groups:  proteins that disrupt the 
target cell membrane and proteins that translocate to the interior of the cell and 
modify substrates.  Examples of the former include pore-forming toxins, such as 
cholesterol-dependent cytolysins (listeriolysin O, perfringolysin O) (201), and 
phospholipases, such as phospholipase-C (193).  Examples of the latter include 
anthrax toxin, tetanus toxin, diphtheria toxin, and large clostridial toxins (LCTs) 
(177, 178).   The membrane active toxins cause cell death by interrupting the 
integrity of cell membranes, causing cell lysis or influx of ions that modulate 
signaling pathways within the cell (201).  In contrast, intracellular bacterial toxins 
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are primarily enzymes that target important substrates within the cytosol and 
disrupt the cell’s capacity to modulate steps in signaling (178).   
 
 Both the membrane active toxins and intracellular bacterial toxins have been the 
focus of substantial studies over the past decades; however, major gaps in our 
knowledge remain.  Mechanisms of toxin gene expression, secretion, membrane 
interaction, membrane translocation, substrate modification, and their impact on 
downstream cellular effectors have been defined in exquisite detail for several 
bacterial toxins (178).  Most of these studies utilize in vitro systems to define toxin 
activity.  Indeed, almost by definition, studies on intracellular bacterial toxins 
involve using immortalized cell lines and, more rarely, primary cells in culture.   
These numerous findings now present the field with a formidable problem:  to 
which cell types should this body of information be applied?  That is, what cell 
types are primarily impacted by bacterial toxins within the host during various 
stages of disease?  
 
A comprehensive understanding of soluble bacterial toxins may depend on 
resolving this issue, since it is becoming increasingly evident that the same 
signaling pathways can modulate many different events in various cell types.  Take 
for example signaling through the small GTPases, which are targeted by LCTs.  In 
some cell types, small GTPases activate apoptosis (32, 49, 93), while in other cell 
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types, small GTPases prevent apoptosis (228).  How then should we interpret 
findings that LCTs inactivate small GTPases in cultured cells?  Is this a pro-
apoptotic or anti-apoptotic event?   To further emphasize this point, consider 
pefringolysin-O (PFO), a pore-forming toxin produced Clostridium perfingens, a 
common cause of gas-gangrene.  PFO rapidly lysis red blood cells, and is often 
classified as a hemolysin (202).  Yet, hemolysis is not known to occur systemically 
in patients with gas-gangrene, raising questions about the relevance of studies 
focused on red blood cells.    Certainly, a great deal has been learned about the 
biophysical aspects of PFO pore-formation, membrane insertion, and cell lysis, 
through use of erythrocytes (69, 90, 181, 213).  But, again, to which cell types 
should we apply this knowledge?   The formation of ion-conducting channels could 
have a substantially different impact on neurons, as opposed to fibroblasts.   For 
these reasons, the field of bacterial toxins is reaching an important crossroad, if 
not an impasse in their study.  With hundreds of immortalized and primary cells 
ranging from stem cells to cardiomyocytes now available, selection of the most 
relevant cell type should be a critical element in the study of particular bacterial 
toxins.   
 
Neurotoxins such as tetanus toxin and botulinium toxin are excellent examples of 
bacterial toxins whose in vivo cell target is known (183).  Both of these toxins have 
a high affinity to presynaptic membranes of neuromuscular junctions and block the 
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action of synaptic transmission (176).  Because the targeted cell types of these 
toxins are known, the impact on the host is well-understood, and we have a more 
comprehensive understanding of the deadly diseases that these toxins cause (3).  
However, for most bacterial toxins, the in vivo targets remain undefined (62).  This 
is especially true for pathogens that cause fulminant disease, where systemic 
effects and multi-organ damage is evident and the toxin is released at the site of 
colonization but can function distal from this site. 
 
Clostridium difficile is an example of a pathogen that primarily colonizes and 
causes disease in the gastrointestinal tract, yet patients suffering with serious and 
fulminant disease exhibit pathologies outside of the original point of colonization 
(35, 44, 91, 138, 174).  Still, it is unknown as to what extent C. difficile’s toxins 
contribute to the morbidity and mortality of these patients.  C. difficile produces two 
toxins, toxin A (TcdA) and toxin B (TcdB) (211).  Both of these toxins inactivate the 
small GTPases Rho, Rac, and Cdc42 via glucosylation, leading to changes in the 
actin cytoskeleton and eventually cell death via apoptosis in vitro (10, 17, 100, 
164).  However, while TcdA is known to be an enterotoxin, TcdB is a cytotoxin with 
little enterotoxic activity in the rabbit illiel loop model (46, 221).  Thus, TcdB is an 
example of a bacterial toxin studied extensively in vitro but whose in vivo activities 
remain poorly understood. 
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How can the systemic targets of bacterial toxins, such as TcdB, be identified?   
Unfortunately, traditional animal models such as rodents and primates are not 
particularly useful in this regard.  These models can be used to follow physiological 
changes like cardiac and respiratory function, but whether these events are due to 
direct or indirect effects of the toxin is difficult to determine. Furthermore, direct 
visualization of the toxin localizing to major organs is limited.  Therefore, in order 
to directly visualize complex anatomical structures and assess toxin localization in 
real-time, a new model was sought that blended the benefits of traditional models 
and overcame their inherent obstacles. To this end, in this dissertation we have 
utilized the developing zebrafish embryo as an animal model to assess the 
tissue and organ specific effects of bacterial toxins, including TcdB (75, 211). 
 
The zebrafish embryo as a model 
The zebrafish, Danio rerio, is a small teleost fish found primarily in fresh water 
streams of India, but is also conveniently available through a variety of vendors.  
Zebrafish diverged from human evolution approximately 450 million years ago, yet 
the zebrafish genome sequence reveals a remarkable degree of similarity to Homo 
sapiens (112).  The overall identity between zebrafish proteins and their human 
orthologues is approximately 70%, but the degree of homology approaches 100% 
when comparisons are made between functional domains of important regulatory 
proteins (113).    Even prior to the sequencing of their genome, George Streisinger 
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recognized zebrafish as a valuable model for the study of development and 
genetic diseases.  From that first insightful description by Dr. Streisinger to now, 
the zebrafish is a widely accepted model for the study of embryonic development 
and genetics as well as infectious diseases (39, 73, 122, 150, 162, 163, 203, 204). 
With now over 8000 publications using zebrafish as a model, clearly Dr. 
Streisinger’s visionary use of this small, tropical fish has led to a better 
understanding of genetics, cellular differentiation, and development. 
 
Zebrafish have several characteristics that make them appealing to researchers, 
including simplicity, fecundicy, transparency, organ similarity, and the availability of 
many transgenic zebrafish with defined phenotypes.  Simplicity: zebrafish and their 
embryos are small (adults are 4-5 cm and embryos are approximately 3 mm), easy 
to maintain, and cost effective, making maintenance and experimental set-up 
straightforward and efficient (Fig. 1).  For example, hundreds of zebrafish can be 
housed in a few aquariums.  Additionally, embryo experiments can be performed in 
96-well plates with as many as 5 fish per well.  This allows for numerous 
experiments and replicates to be carried out at one time under tightly controlled 
conditions.  Furthermore, because of their small size, pathology and 
immunohistochemistry can be performed on the whole animal with the entire fish 
cross-sectioned on the sagittal plane (Fig. 2).    Fecundicy: A single mating can 
provide hundreds of embryos, making it possible to perform high throughput 
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analysis under a variety of conditions and statistical significance.  Transparency:  
Arguably, the most appealing characteristic of the zebrafish model is that zebrafish  
 9
Fig. 1  Zebrafish intoxication assay.  Zebrafish are first mated and embryos are 
collected.  Next, prepared embryos are distributed into a 96-well plate containing 
embryo water, with up to five embryos per well.  At selected time points, toxin is 
added directly to the well and the zebrafish are observed for changes in 
phenotype and histopathology and/or immunostaining can be performed.  Various 
iterations of this assay include addition of candidate inhibitors against the toxin to 
test efficacy (76). 
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Fig. 2.  Histopathology of zebrafish whole-body cross-sections.  Shown in 
the panel are four examples of prepared zebrafish larva cross-sectioned on a 
sagittal plane and subjected to histopathology.  Using this approach it is possible 
to visualize many or all of the major organs for damage following exposure to 
bacterial toxins (76).  
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embryos are optically transparent for the first 10 days of development and growth, 
circumventing the inherent problems with post-mortem analysis of tissue and 
organ damage.  Such transparency makes it possible to directly visualize the 
major organs and the vascular system within the zebrafish embryo (Fig. 3).  By 
taking of advantage of this unique quality, following intoxication, researchers can 
directly determine where labeled toxin localizes, the sequential progression of 
damage, and which cell types and tissues are damaged in real-time.  Organ 
system similarity:  Zebrafish possess many of the same organs as humans, such 
as heart, gastrointestinal tract, liver, pancreas, gallbladder, and kidneys, to name a 
few, making the transparent embryos a powerful model to study organogenesis, 
organ function, and organ-related disorders and diseases, as well as exogenously-
induced organ damage (113).  Mutant Phenotypes:  The zebrafish embryo has 
been used extensively to identify genes involved in stages of development and 
function of various organs and systems (73).  Because of this, numerous zebrafish 
phenotypes and their related mutations have been identified, leading to several 
databases of zebrafish mutant phenotypes with known genetic defects.  Overall, 
with these characteristics combined, zebrafish embryos provide a unique and 
valuable model to study human disease and have recently been used to 
characterize the in vivo targets of bacterial toxins, such as TcdB.  In the following 
chapter, we highlight an important clinical problem to which the zebrafish model 
can be applied:  Clostridium difficile-associated disease.   
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Fig. 3.  Visualization of major organs in the transparent zebrafish 
embryo.  Shown here is a zebrafish embryo 4 days post-fertilization.  By 
simple light microscopy, major internal organs within the fish are easily 
visualized.  Because of this transparency, damage to major organs can be 
observed in real-time. 
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CHAPTER II 
 
LITERATURE REVIEW OF CLOSTRIDIUM DIFFICILE 
A.  Clostridium difficile 
 
Over the years, public concern over hospital-acquired infections has primarily 
focused on methicillin-resistant Staphylococcus aureus (MRSA). However, recent 
reports indicate that Clostridium difficile, the causative agent of Clostridium 
difficile-associated disease (CDAD), has caused nearly twice the number of 
nosocomial infections and related deaths compared to MRSA (139).  Outbreaks 
and epidemics of CDAD have been reported in the United Kingdom, Europe, 
Canada, and now the United States (138, 156, 210).  Coupled with a disturbing 
and somewhat sudden increase in mortality rate, the once moderate, self-limiting 
disease has now become an increasing and sometimes fatal problem (139).  Even 
prior to recent media recognition, C. difficile has been the leading cause of 
antibiotic-associated diarrhea (AAD) and pseudomembranous colitis (PMC).  
However, it was not until the late 1970’s that C. difficile was recognized as a 
human pathogen, nearly 40 years after its original isolation.   
 
In 1935, Hall and O’Toole isolated C. difficile from the meconium and feces of 
healthy infants and named it Bacillus difficilis due to culturing and isolation 
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difficulties (74).  Shortly thereafter, the bacterium was reclassified into the genus 
Clostridium (from greek:  small spindle), and thus was renamed Clostridium 
difficile and first listed in the 5th edition of Bergey’s Manual of Systematic 
Bacteriology in 1939.  C. difficile is a Gram-positive, anaerobic rod, approximately 
3-5 μm in length, and is motile with peritrichous flagella (Fig. 4).  C. difficile also 
forms an oval, subterminal to terminal spore (Fig. 4).  Further characterization 
revealed that C. difficile culture filtrates were lethal when injected into animals 
(74), and in 1937, C. difficile antiserum was shown to neutralize toxic activity 
(184).   However, it would be several decades before C. difficile was found to 
cause disease.   
 
B.  Clostridium difficile-associated disease 
 
Pseudomembranous colitis was first reported in 1893 when pseudomembranous 
lesions of the colon were observed in a post-operative patient and termed 
“diphtheritic colitis” (54).   However, in 1977, another clostridium, Clostridium 
sordelli, was implicated as the causative agent of PMC.  In 1977, Rifkin et al found 
that antisera to C. sordelli neutralized the cytotoxic activity found in the feces of 
PMC patients (114, 169).  Yet curiously, C. sordelli could not be isolated from the 
PMC patient feces while C. difficile consistently was.  Also in the late 1970’s 
several groups demonstrated that C. difficile was the etiological agent of antibiotic- 
 18
 
Fig. 4.  Gram-stain of Clostridium difficile and example of C. difficile 
with flagella (40).   
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induced colitis in hamsters (125).  These and other studies finally linked the 
formerly non-pathogenic C. difficile to PMC and AAD, decades following its original 
isolation. 
 
As a nosocomial disease, CDAD is most often found in the hospital or primary care 
facilities, although there are several cases outside these settings (152).  The 
reservoirs in hospitals are commonly patients, health care workers, and 
contaminated environments (104).  C. difficile has been isolated from healthcare 
workers, patients, hospital therapy dogs as well as fomites including hospital 
toilets, clothing, carpet, blood pressure cuffs, call buttons, and telephones (51, 94, 
104, 108, 116).  Of particular concern, C. difficile can persist even after typical 
disinfecting techniques, indicating that standard infection control methods can be 
ineffective (14). Because it can exist as an inert and hearty spore, this bacterium is 
the bane of many hospitals, as common techniques of disinfection (i.e. alcohol-
based sanitation) are not sporicidial.   
 
As a pathogen, C. difficile is unique in that in order for the bacterium to initiate 
disease the host usually must be exposed to antibiotics (typically clindamycin, 
cephalosporins, ampicillin, and, more recently, fluoroquinolones) (125, 156).  
Infection with the bacterium can occur either pre- or post- antibiotic therapy (8).   
The widely accepted dogma of C. difficile infections is transmission of bacterium 
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via fecal-oral route, colonization of the gastrointestinal tract, disruption of colonic 
microflora by antibiotics, and growth and proliferation of C. difficile followed by 
toxin production, and damage to the intestinal mucosa.  In addition to antibiotics, 
other people at risk for CDAD include immunocompromised patients, persons with 
cystic fibrosis, individuals undergoing chemotherapy, and proton pump inhibitor 
therapy (7, 42, 88, 133) 
 
Following transmission of C. difficile and host exposure to antibiotics, C. difficile 
can proliferate and cause disease (57, 145, 189).  The following summary can be 
found in detail in Kelly, et al 1994 (105).  In mild CDAD, diarrhea consists of 
approximately 3 unformed stools within a 24 h time period and is usually self-
limiting.  As CDAD worsens, diarrhea becomes more perfuse and contains 
mucous, abdominal cramping ensues, and a sigmoidoscopy (an internal 
examination of the colon) may reveal erythematous bowel walls but no 
pseudomembranes. In addition, patients may complain of symptoms outside of the 
gastrointestinal system such as nausea, fatigue, low-grade fever, anorexia, and 
general malaise.   
 
In more serious cases of CDAD, sigmoidoscopy reveals erythematous bowel walls 
as well as small, raised, yellow-white lesions within the colon (Fig. 5A).  In early 
PMC, these lesions are small (2 to 10 mm) and most of the inflammation is  
 22
Fig. 5  Colonic etiology and pathology of CDAD.  Panel A and B show the 
progression of severe CDAD.   Panel A  illustrates the formation of small white 
lesions that increase in size and number until they coalesce to form a 
pseudomembrane within the colon (Panel B).  Panel C represents the typical 
“volcano” lesions in C. difficile colitis (104). 
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confined to the superficial epithelium. As disease progresses, basal laminia 
inflammation is extensive and more lesions form and coalesce, creating a 
“pseudomembrane” of immune cells, mucus, and necrotic tissue within the colon 
(Fig. 5B).  Pathology of PMC reveals eruptive “volcano” lesions caused by the 
release of mucus, serum proteins, inflammatory cells, and necrotic tissue (Fig. 
5C).  Patients exhibit persistent diarrhea, high fever, abdominal cramping, diffuse 
lower quadrant pain, and nausea.  Furthermore, leukocytosis can be detected 
(>20,000/L).    
 
As disease becomes fulminant, abdominal pain can become severe and colonic 
distension can occur (also referred to as toxic megacolon) (36).  Contrary to mild 
and moderate forms of CDAD, diarrhea at this stage of disease can be minimal as 
paralytic ileus may develop, causing a loss in the normal contractile movements of 
the intestinal wall, colonic dysmotility and a pooling of colonic secretions.  Because 
diarrhea is a hallmark of CDAD, lack of diarrhea in these cases can lead to 
misdiagnosis. Leukocytosis can be >35,000 cells/mm3 and upwards to 50,000 
cells/mm3 (36).  This increase in WBC can be used as an indicator of impending 
fulminant disease.  Patients with WBC of >35,000 cells/mm3 are associated with a 
poor prognosis and a high mortality rate (50%) (130). Heart rate in patients with 
fulminant CDAD is >120 with tachycardia present and patients often require 
mechanical intubation (36).   
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In severe cases of CDAD, systemic damage outside of the gastrointestinal tract is 
detected with documented reports of cardiopulmonary arrest (138), acute 
respiratory distress syndrome (91), multiple organ failure (44), renal failure (35), 
and liver damage (174). Although perforations of the colon can occur, there are 
numerous cases indicating that death occurs prior to free air and perforation of the 
colon (36).  Furthermore, circulating TcdB has been detected in serum and ascitic 
fluid (166) and patients are known to generate serum antibodies against toxin 
(206, 215). These data, coupled with the low incidence of C. difficile in the 
bloodstream (52) (personal communication with Stuart Johnson and Dale Gerding, 
MD VA hospital, Chicago), indicated that systemic events may be due to the 
release of bacterial toxins into the bloodstream and not sepsis.    
 
Following presentation of the aforementioned clinical symptoms, several methods 
can be used to diagnose CDAD.  The direct fecal cytotoxicity test is the “gold 
standard” and assays for the presence of toxin by observing specific toxin-induced 
changes in tissue culture cell morphology (45).  This test is not the most sensitive, 
but it is the most specific as it determines the presence of toxin-expressing strains 
of C. difficile.  Conversely, the stool culture test is not the most specific as it does 
not distinguish between toxigenic and nontoxigenic C. difficile; but, it is the most 
sensitive (136).  Sigmoidoscopy is rapid but only detects 50% of 
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pseudomembranes (15).  In general, however, the most frequently used test is the 
EIA test for TcdA and TcdB that detects the presence of these toxins within the 
feces of CDAD patients.  Because some strains of C. difficile do not produce TcdA, 
it is important that diagnostic tests assay for TcdB (136).   
 
For treatment of CDAD, often discontinuation of the offending antibiotic can result 
in the resolution of mild cases (105).  If this fails, treatment of CDAD routinely 
consists of oral metronidazole or vancomycin for 7-10 days (105).  Metronidazole, 
which disrupts nucleic acid synthesis, is the first drug of choice primarily because it 
is the least expensive; however, because of emerging metronidazole-resistant 
strains of C. difficile, a potential decrease in efficacy, and the negative, systemic 
side effects of metronidazole, vancomycin is also used (5).  Vancomycin, which 
inhibits cell wall synthesis, is very effective in treating CDAD (5).  Most importantly, 
because it is poorly absorbed in the gastrointestinal tract (in contrast to 
metronidazole), significant luminal levels of vancomycin can be obtained (50-200 
fold higher than the MIC) without systemic effects (95).  However, vancomycin is 
expensive and is rarely used at the advice of the Hospital Infection Control 
Practices Advisory Committee due to an increasing threat of vancomycin-resistant 
enterococci and staphylococci (although there are contrasting reports as to the 
relevance of this) (66). 
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Unfortunately, in addition to emerging antibiotic resistant strains of C. difficile, both 
metronidazole and vancomycin have been associated with C. difficile cecitis (12, 
13); therefore, new antibiotics are being sought for the treatment of CDAD.  
Antibiotics such as nitazoxamide (148), rifaximin (175), ramoplanin (58), and 
teicoplanin (218) have some preliminary success in clinical trials.  Additionally, 
unlike vancomycin and metronidazole, nitazoxamide does not induce C. difficile 
cecitis (140).  However, these antibiotics are not yet approved for the treatment of 
CDAD by the FDA, although nitazoxamide and ramoplanin are currently in phase 
III trials for FDA approval (11).  Teicoplanin is currently used in the UK and Europe 
for treatment of CDAD but as of yet, is not clinical available in the United States 
(11).  
 
Because disease symptoms and pathologies are due to the production of toxin, 
companies have also started developing drugs that are directed against TcdA and 
TcdB.  There are several approaches such as anion-exchange resins and toxin 
binding polymers as well as antibodies against the toxins.  Anion-exchange resins 
(cholestyramine and cholestipol) are used to bind the toxins (11).  Yet, while these 
resins bind successfully to the toxins in vitro, they were found to be ineffective as 
treatments in the hamster model and clinical trials. Thus these treatments are not 
recommended for use in severe cases (11, 24).  Furthermore, cholestyramine was 
also found to bind to vancomycin (191).   
 28
Tolevamer, a sodium salt of styrene sulfonate polymer, has shown success in 
hamster infection trials with up to 80% of hamster survival compared to 10% with 
cholestyramine (123).  Although compared to vancomycin in clinical trials, there is 
no significant difference in initial response; there may be a trend for a faster 
response with vancomycin but fewer reoccurrence using the tolevamer therapy.  
Clearly further studies are needed to determine the efficacy of tolevamer.  Yet, it 
appears to be a promising alternative or concomitant therapy to antibiotics and is 
currently in phase III trails for FDA approval (11).   
 
Animal studies have shown that vaccination with culture filtrates containing 
inactive TcdA and TcdB provided immune protection against disease (53, 109, 118, 
195, 196). Additionally, researchers have shown that antibodies directed against 
TcdA and TcdB have been somewhat effective at preventing disease in the 
hamster infection model.  In these studies, anti-TcdA alone could provide some 
protection while anti-TcdB provided little protection; however, both anti-TcdA and 
anti-TcdB were required for the greatest protection (110).  Currently, a toxoid 
vaccine and monoclonal antibodies to TcdA and TcdB are in phase I trials and 
phase II trials, respectively (11).  It is important to note that all of these toxin-based 
therapeutics not only provide potential alternatives to antibiotic therapy but also 
reiterate the important role of C. difficile’s toxins in CDAD.           
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There are also several other alternative approaches to prevention, treatment, and 
management of CDAD.  Probiotics, prophylactics, and immune therapy are just a 
few alternatives to antibiotics and anti-toxin drugs.  Probiotics are defined as 
supplements (food, drugs, etc) containing live, “beneficial” bacteria (188).  This 
form of therapy is designed to favorably alter the microflora of the gastrointestinal 
tract in order to promote better digestion and, most importantly, prevent pathogens 
from causing disease.  The most common include Lactobacillus sp. and 
Saccharomyces boulardii (188). Although probiotics can be found in drugstores 
and supermarkets, their place in standard treatment practice is not yet established.  
Although there appears to be a great deal of promise in using “friendly bacteria” to 
prevent the colonization and proliferation of C. difficile, research in probiotics as 
therapeutics for enteric disease is mired in single case reports,  in vitro only 
studies, and loosely designed clinical studies.  Therefore, more research and 
larger, tightly controlled clinical studies will need to be performed before it 
becomes standard practice.   
 
Fecal bacteriotherapy, often considered the ultimate human probiotic therapy, has 
been around for more than 40 years in humans and perhaps as early as the 17th 
century in animals and has been used to treat not just CDAD but also ulcerative 
colits, irritable bowel syndrome, inflammatory bowel disease, and even 
constipation (19).  Essentially, 5-300 g of donor stool is collected, screened for 
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pathogens, suspended in saline, filtered, and administered during a colonoscopy 
or as an enema or through tubes (enteric, duodenal, jejunium, or nasogastric).  
Although controversial, fecal implants may prove to be efficacious (in one report, 
33 out of 36 (92%) patients with refractory CDAD resolved symptoms following a 
single fecal implant) and this therapy may be useful in preventing reoccurring 
CDAD (18, 19, 56, 124, 157, 200).  Despite the aesthetics, administration of the 
therapy, and potential for infection, this area of probiotic therapy is promising; 
however, more studies are needed with more patients and better controls to fully 
address the usefulness of this treatment.  
 
Finally, another area in therapy is immune therapy.  In order to boost serum 
antitoxin antibody levels, immune therapy with intravenous immunoglobin (IVIG) 
has been investigated.  In a study by Leung et al., 5 children with recurrent CDAD 
and low serum IgG antitoxin A were given IVIG every three weeks for 4-6 months.  
All 5 showed marked improvement and tested negative for TcdB in the stool 
cytotoxicity assay (117).  Other studies also reports IVIG success in treating 
recurrent CDAD and after no response to antibiotic therapy (11).  Patients that 
suffer from severe and/or recurrent CDAD are often unable to mount a proper 
immune response and have low levels serum antitoxin antibodies; therefore the 
use of IVIG may be useful in treating severe and recurrent disease and is currently 
in Phase IV trials (11). 
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Recurrent CDAD is a continuing problem and occurs usually 1-10 days post-
CDAD-specific antibiotic therapy (11).  Recurrent disease occurs frequently 
(approximately 30% of CDAD patients) and may be attributed to either C. difficile’s 
ability to form a spore or re-infection with a new strain of C. difficile.  Following 
cessation of antibiotic therapy and “eradication” of vegetative, active C. difficile, 
inactive and antibiotic resistant spores can still remain in the gastrointestinal tract.  
If the patients are still immunosuppressed, continuing other antibiotics or 
immunosuppressive drugs, or the suppressive colonic microflora has yet to re-
colonize the gastrointestinal tract, the remaining C. difficile spores can become 
active or a new strain may colonize the patient and cause disease.  Probiotics, 
immune therapy, fecal implants, tapering doses of antibiotic, and pulse antibiotics 
are all used for treatment of recurrent disease (11). 
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C. The Toxins of C. difficile and their role in disease 
 
Introduction and overview 
Following its isolation and identification in 1935, researchers discovered that C. 
difficile culture filtrate caused lesions, respiratory arrest, and death in animals 
upon injection (74); however, C. difficile was not recognized as a human pathogen 
at this time, thus for decades, little was known about its virulence factors.  
Interestingly, it was the bacterium’s toxins that led to the correlation between PMC 
and AAD and infection with C. difficile, nearly 4 decades after the bacterium’s 
original isolation.   
 
In the 1970s, the feces of PMC patients demonstrated cytotoxic activity (125). 
Accordingly, researchers began to investigate the possibility of a toxin-producing 
bacterium as the cause.  As a result of this research, it was discovered that the 
cytotoxic activity was neutralized by a gas gangrene antiserum against a mixture 
of clostridial species (125).   From this mixture, investigators demonstrated that 
only C. sordelli antiserum neutralized the toxin present in PMC fecal samples, 
originally implicating C. sordelli as etiological agent of PMC infections.  However, 
C. difficile was soon identified as the causative agent of PMC and that it produced 
a toxin similar to that of C. sordelli (thereby explaining the cross-reactivity of the 
antiserum) (125) It was not until 1980 that researchers demonstrated that C. 
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difficile actually produced two separate toxins, toxin A (TcdA), an enterotoxin, and 
toxin B (TcdB), a potent cytotoxin (6, 192).   
 
TcdA and TcdB belong to a larger class of intracellular bacterial toxins termed the 
Large Clostridial Toxins, or LCTs.  These toxins are produced by several 
pathogenic Clostridia species including Clostridium difficile, Clostridium sordelli, 
and Clostridium novyi and are characterized by their large size and their 
mechanism of action (16, 177). LCTs are some of the largest bacterial toxins 
known, with molecular masses ranging from ~250-308 kDa (16, 177).  Members of 
the LCT family are typical act intracellularly as glucosyltransferases, targeting and 
inactivating proteins in the Rho and Ras family of GTPases via the addition of a 
sugar moiety within the effector binding region.  The disruption of small GTPase 
signaling in cells results in disaggregation of the actin cytoskeleton and cell death 
(16, 177, 210). 
 
As members of the LCT family, TcdA and TcdB share sequence homology and are 
large in size (TcdA = 308 kDa and TcdB = 270 kDa).  Additionally, both TcdA and 
TcdB inactivate Rho, Rac, and Cdc42 by transferring glucose from UDP-glucose to 
a reactive threonine in the effector-binding region of the GTPases, resulting in their 
inactivation(16, 55, 98, 99).  Despite their similarity, TcdA and TcdB differ in their 
biological activity in vitro and in vivo.  TcdA is classified as an enterotoxin while 
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TcdB is a more potent cytotoxin with very little enterotoxic activity (118, 119, 126, 
127). Both TcdA and TcdB are important contributors to disease and much is 
known about these two major virulence factors; therefore, in addition to this 
dissertation, there are several elegant reviews that detail several aspects of these 
toxins and their role in CDAD (125, 210). 
 
  
Genetics of TcdA and TcdB 
The genes encoding for TcdA and TcdB are 8133 and 7098 nucleotides in length, 
respectively, share 66% nucleotide sequence homology, and like the genome of C. 
difficile, tcdA and tcdB have a low G+C content (<28%) (47).    Given their size, 
sequence homology, functional similarity, and proximal location (only 1350 
nucleotides separate the genes), it is thought that these genes may be the result 
of a duplication event (209).    Both of these genes are located on the C. difficile 
chromosome within a 19.6 kilobase pathogenicity locus, along with three other 
accessory genes tcdC, tcdD, and tcdE, which are organized as tcdDBEA and tcdC 
(Fig. 6A) (77). 
 
The accessory genes tcdC,D,E, are believed to be involved in the regulation of 
TcdA and TcdB production and release. Located downstream from tcdA, tcdC is 
divergently transcribed from the toxin genes and hypothesized to negatively  
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Fig. 6.  Pathogenicity island of C. difficile and proposed protein domain 
structures of its toxins, TcdA and TcdB.  Panel A represents the genetic 
arrangement of the toxin genes and their accessory genes, tcdCDE within the 
pathogenicity locus of the C. difficile genome.  Panel B portrays the 3 domain 
structure of TcdA and TcdB, including the enzymatic region, the translocation 
domain, and the receptor-binding domain.  Also specified in this drawing are 
regions of specific activities including the glucosyltransferases activity located at 
the amino terminus, the region required for receptor binding, and the motifs 
required for toxin activity, including W102, DXD, and the CROP regions (210).    
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regulate the expression of TcdA and TcdB (87).  TcdC expression begins in early 
exponential phase but declines when growth enters into stationary phase. 
Additionally, during high transcription levels of tcdC, there is a corresponding low 
level of transcription of tcdA,B,D,E.  Isolations of C. difficile strains that have a 18-
basepair deletion in their tcdC genes or carry a mutation that results in the 
production of a truncated TcdC protein are found to produce 16 -20 fold more TcdA 
and TcdB, respectively (214).  Collectively, these data suggest that TcdC is a 
negative regulator of TcdA and TcdB production. 
 
The gene tcdD (also known as txeR), is located upstream of tcdB and is proposed 
to positively regulate the expression of tcdA and tcdB (87).  Using promoter 
reporter fusions of the tcdA and tcdB promoter-binding region, TcdD was found to 
enhance their expression (146).  Furthermore, the protein sequence of TcdD 
reveals homology to DNA binding proteins, UviA (which regulates the C. 
perfringens UV-inducible bacteriocin gene) (63), as well as TetR and BotR, which 
positively regulate the expression of tetanus toxin and botulinum toxin, 
respectively (131, 132).  The transcription of tcdD also coincides with the 
expression of tcdA,B,E in the late growth phase (87). 
 
The function of TcdE in C. difficile is still poorly understood.  Also expressed in late 
growth phase, tcdE has homology to several holins (a bacteriophage protein that 
 38
disrupts cell membranes) (87, 190).  C. difficile does not possess a known 
secretion system; therefore, it has been proposed that TcdE causes the lysis of C. 
difficile resulting in the release its large toxins.  Tan, et al demonstrated that TcdE 
has structure and function similarity to holin proteins; however, the precise 
purpose of TcdE in C. difficile is still currently under investigation (190). 
 
Although it is known that expression of TcdA and TcdB occurs in the late growth 
phase (87), little is known regarding the environmental signals that regulate toxin 
expression. Given the association between antibiotics use and CDAD, many 
researchers have sought to prove that antibiotics directly induce toxin expression.  
Early studies reported that addition of antibiotics in vitro increased the cytotoxic 
activity of C. difficile (65, 149).   However, it is important to note that toxin 
production in response to antibiotics varied from strain to strain and even antibiotic 
type and does not occur in all toxigenic isolates of C. difficile (65, 149).  Therefore, 
while some reports indicate a correlation between antibiotics and toxin expression 
and production, there has not yet been definitive evidence to support this.   
 
In C. perfringens and C. botulinum, enterotoxin production has been linked with 
sporulation (59, 60, 226).  Yet, this does not appear to occur in C. difficile as 
mutants deficient in sporulation are still capable of producing toxin and toxin 
cannot be extracted from spores (106, 107). Numerous studies reveal other 
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signals that may regulate toxin expression. Yamakawa, et al found that limiting 
biotin resulted in a 35-64-fold increase in TcdA and TcdB expression, respectively 
(225).  Rapidly metabolizable sugars, such as glucose, are found to repress toxin 
synthesis (48).  Another group reported that toxin synthesis is responsive to 
certain amino acids, metabolic by-products such as butyric acid and butanol and 
temperature (101, 102).   
 
Quorum sensing is a means of bacterial cell-cell communication that involves the 
production, secretion, and detection of extracellular signal molecules called 
autoinducers (216). Bacteria often use quorum sensing to regulate gene 
expression, and recently, it has been reported that C. difficile uses the quorum-
sensing molecule, LuxS/autoinducer-2, to regulate the transcription of tcdA, tcdB, 
and tcdE (28, 115). Given that:  1) quorum sensing is cell density-dependent, 2) 
disease occurs following the overgrowth of C. difficile in the gastrointestinal 
system, and 3) the production of toxin occurs in the late-log and stationary phase 
of C. difficile growth, it will be important to further understand the role of quorum 
sensing in the regulation of C. difficile toxin production. 
 
Although numerous environmental stimuli have been shown to influence toxin 
production, how these signals regulate toxin expression, which genes are 
specifically involved, and what actually occurs in vivo is unclear.  Unfortunately, 
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because C. difficile currently lacks a genetic system, it is difficult to fully elucidate 
the function and role of tcdABCDE in pathogenesis and what specifically 
coordinates the expression of TcdA and TcdB and is clearly an under-studied area 
of C. difficile pathogenesis.   
 
Toxin structure and mechanism of action  
Despite their size, TcdA and TcdB, like all LCTs, are single polypeptide proteins 
and can be roughly divided into three functionally different regions:  the enzymatic 
region, the membrane translocation domain, and the receptor-binding domain (Fig. 
6B) (210).    
 
The N-terminal enzymatic domain of TcdA and TcdB 
The amino terminal end of TcdA and TcdB contains the enzymatic region, and not 
surprisingly, this region shares homology between other LCTs and other 
glucosyltransferases (168).  As shown in Fig 6B, the glucosyltransferase activity 
appears to be within the first 546 residues (84, 186), although Wagenknecht-
Wiesner found that only residues 1-467 is required for in vitro glucosylation of Rho, 
Rac, and Cdc42 (212).  Within this enzymatic region is a conserved DXD motif, 
which is important for carbohydrate binding in divalent cation-dependent, sugar-
nucleoside diphosphate glucosyltransferases, like the LCTs and numerous other 
mammalian glucosyltransferase families (220).  Indeed, a mutation of the DXD 
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motif in C. sordelli lethal toxin (TcsL) prevented toxin-mediated glucosylation of 
GTPases in vitro (26).  Also conserved among the LCTs, tryptophan-102 was 
found to be involved in UDP-glucose binding, an event required for toxin activity 
(25).  To determine the portion of the amino-terminus that comprises the region of 
substrate specificity, investigators created chimeric hybrids between TcdB and 
TcsL, as TcdB glucosylates Rho, Rac, and Cdc42 while TcsL targets Rac, Ras, 
Rap, and Ral.  The construction of these toxin hybrids revealed that the region 
conferring substrate specificity of TcdB is located at residues 264 to 516 (83).  
 
The C-terminal binding domain of TcdA and TcdB 
The highly repetitive C-terminal region and the middle region of the LCTs are 
required for the internalization of the toxin via receptor-mediated endocytosis.  
Very little is known about middle region; however, it is proposed to be the 
membrane-inserting translocation region (208). The C-terminal region is believed 
to be the receptor-binding region. Frisch, et al found that this region of TcdA is 
required for endocytosis (61). Furthermore, recombinant fragments of this region 
and antibodies against this region provide protection against the toxin.  
 
Within the C-terminus are several short (21-50 residues) homologous regions 
termed the combined repetitive oligopeptides or CROPs (209) (Fig. 6B).  TcdA and 
TcdB both encode for 5 groups of CROPs but TcdB only shares homology with four 
 42
of TcdA’s CROPs, perhaps explaining the difference in host cell tropism between 
the two toxins. Although this region varies between LCTs, these toxins are all rich 
in aromatic amino acids and there is a consensus YYF triad. These repeats are 
similar to those found in the carbohydrate-binding region of streptococcal 
glucosyltranserases (224).  Importantly, the receptor for TcdA and TcdB, as well as 
the other LCTs, is believed to be nonproteinaceous, most likely carbohydrate in 
nature (210). While there are several examples of aromatic amino acids-
carbohydrate interaction and they are believed to be important in carbohydrate 
receptor binding, the specific function of these repeats is still poorly understood 
(209).   
 
Receptor-binding 
Both TcdA and TcdB are intracellular bacterial toxins and thus must gain access to 
the cell cytosol in order to modify their targeted substrates (See Fig. 7 for general 
intoxication schematic).  To do this, TcdA and TcdB first bind to cell surface 
receptors, which are believed to be carbohydrate in nature (210).  Although TcdB’s 
receptor is currently unknown, TcdA has been shown to bind to Galα1-3Galβ1-
4GlcNac carbohydrates; unfortunately, these do not appear to be present on 
human cells (111).  Sucrase-isomaltase may also be another possible receptor for 
TcdA, yet it too is not found on human colon cells (161). The minimum  
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Fig. 7.  Internalization schematic of TcdA/B.  Upon binding to toxin receptor, 
TcdA/B is internalized into the host cell via receptor-mediated endocytosis.  Upon 
acidification of the endosome, the enzymatic region is released into the cytosol 
where it can transfer a sugar moiety from UDP-glucose into the effector-binding 
region of Rho, Rac, and Cdc42, thereby rendering these small GTPases inactive.  
These events lead to actin condensation, transcription activation, and eventually, 
cell death, via apoptosis (210).     
 44
 
 
 45
carbohydrate receptor Galβ1-4GlcNac has been found on the human I, X, and Y 
blood antigens, but the functional role of this receptor is unknown (198).  
Therefore, while several carbohydrates have been found to bind to TcdA, a 
functional human ligand has not yet been definitively elucidated. 
 
Although TcdB’s receptor is unknown, experimental data suggest that it is different 
from the TcdA receptor and, unlike TcdA, which binds to the apical site of colonic T-
84 cells, the receptor for TcdB appears to be basolaterally located on T-84 cells 
(31). Furthermore, because it is able to intoxicate a wide variety of cell types, the 
TcdB receptor is believed to be ubiquitous (210).  
 
Receptor-mediated internalization of TcdA and TcdB. 
Following binding to the receptor, TcdA and TcdB are then internalized via 
receptor-mediated endocytosis (9, 55, 81).  Upon acidification of the endosome, 
the enzymatic region, of the toxin is released into the cytosol.  Endosome 
acidification is a required step for intoxication as lysosomotropic inhibitors 
(ammonium chloride, hydroxychloroquine, chloroquine, and bafilomycin A) prevent 
toxin activity (55).  The low pH of the endosome is believed to induce the required 
structural changes in the toxin, causing the hydrophobic region of the toxin to be 
exposed for insertion into the target membrane by channel formation (9, 165).  
Next, like many other AB-toxins, the toxin is cleaved and the first 543 amino acids 
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of the enzymatic region is released into the cytosol, an event proposed to take 
place following translocation into the cytosol where it is able to access the toxin 
targets, Rho, Rac, and Cdc42; however, how and where in the cell this cleavage 
occurs is not known (173).   
 
Toxin targets and mechanism of action 
Following release into the cytosol, TcdA and TcdB target the Rho proteins, Rho, 
Rac, and Cdc42.  These proteins are important for regulation of wide variety of 
cellular activities.  Rho has been found to be involved in the regulation of stress 
fiber formation, focal adhesions, and cell contractility (151).  Rac and Cdc42 is 
important for the regulation of lamellipodium and filopodium formation (151, 153).  
Members of the Rho family are regulated by a GTPase cycle.  The following 
summary can be found in detail in a thorough review by Jaffe et al (92).  The GDP-
bound Rho, Rac, and Cdc42 proteins are inactive and regulated by guanine 
nucleotide dissociation inhibitors (GDIs).  These proteins block the activity of the 
guanine nucleotide exchange factors (GEFs) and maintain the proteins in the 
cytosol. Following dissociation of the GDIs, Rho is then cycled to the membrane, 
where GEFs then assist in the dissociation of GDP, allowing Rho to bind to GTP 
and become activated.  In the active, GTP-bound form, the Rho proteins are able 
to interact with numerous downstream targets and effectors.  Following the 
hydrolysis of the γ-phosphate of GTP to GDP, which is facilitated not only by the 
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intrinsic activity of Rho proteins but also by GTPase activating proteins (GAPs), 
the active state is terminated and the proteins return to the inactive, GDP-bound 
state. 
 
TcdA and TcdB glucosylate Rho, Rac, and Cdc42 at a reactive threonine residue:  
Thr37 of Rho and Thr35 in Rac and Cdc42 (99, 100).  The addition of glucose to 
these residues could have several outcomes. Reports indicate that the 
glucosylation of Rho/Ras proteins prevents them from directly interacting with their 
downstream effectors (82, 180).  In studies with Ras proteins, it was shown that 
glucosylation prevents the structural change from the inactive to the active 
conformation (68, 205).  Furthermore, glucosylation may also prevent Rho proteins 
from becoming activated by GEFs (82, 180).    
 
Another consequence of glucosylation by TcdA and TcdB is the up-regulation of 
RhoB, which remains in the activated state while only a small pool of RhoB is 
partially glucosylated by the toxin (67).  RhoB is up-regulated during cellular stress 
and is also known to be involved in apoptotic pathways and may be due to the 
glucosylation and inactivation of proteins such as Rac1 (67).  Therefore, in 
addition to inactivating Rho, Rac, and Cdc42, these toxins also are capable of 
upregulating RhoB, which may contribute to the detrimental effects of the toxins. 
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The biological activity of TcdA and TcdB 
The most prominent effect of TcdA and TcdB on the cell is the drastic changes in 
cell morphology, an unsurprising result given the role of Rho, Rac, and Cdc42 in 
the regulation of the actin cytoskeleton.  Following intoxication, TcdA and TcdB 
induce a type of cytopathic effect (CPE) where the body of the cell retracts, but 
radiating, neurite-like cellular protrusions remain, an effect referred to as 
actinomorphism or arborization (Fig. 8) (143).  This appears to be substrate-
specific as a variant TcdB from C. difficile 1470 which inactivates Rac, Ras, Rap, 
and Ral, produces a cell rounding effect similar to that of TcsL, which targets the 
same substrates (30).  
 
In addition to cell rounding, TcdA and TcdB have also been found to increase 
paracellular permeability and disrupt epithelial membrane integrity (80, 153). Tight 
junctions are important for the cell-to-cell association and barrier function (71) and, 
in an intestinal T84 monolayer model, treatment with toxin resulted in the 
disruption of epithelial tight junctions and changes in F-actin organization in the 
apical and basal membranes (153).  This event was also associated with the 
dissociation of tight junction proteins, ZO-1, ZO-2, and occludin (153).  These 
proteins are important for not only forming the scaffolding between cells but also 
regulating the paracellular barrier (135).  Therefore, disruption of these important  
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Fig. 8.  Representative photographs of Pac2 zebrafish fibroblasts.  The left 
panel shows zebrafish fibroblasts treated with heat-inactivated TcdB.  The right 
panel reveals zebrafish fibroblasts 2 hours post-treatment with TcdB.  Intoxicated 
cells undergo morphological changes termed “arborization” or “actinomorphic,” 
where the cell body retracts but retains “neurite-like” protrusions.       
 50
Heat-inactivated TcdB TcdB 
 51
cellular properties and increases in paracellular permeability would clearly 
contribute to the pathophysiology of CDAD patients.   
 
Although the targeted substrates of TcdA and TcdB are similar, TcdB is 4-fold to 
200-fold more cytotoxic than TcdA, depending on cell type (210).  Several 
investigations have revealed that TcdA has a lower enzymatic activity (31) and 
Vmax (33) compared to TcdB and that following microinjection into the cell, TcdB 
demonstrated a significant difference in cytotoxicity compared to TcdA (31).  The 
difference in cytotoxicity can also be attributed to the differences in the TcdA and 
TcdB receptor-binding domain and cell-surface receptor availability (210).  
 
Both TcdA and TcdB induce cell death via apoptosis (22, 164).  Members of the 
Rho GTPase family are known to regulate cell growth and survival pathways and 
thus their inactivation can promote cell death pathways via apoptosis (154, 179).  
In addition to inducing cell death via the inactivation of small GTPases, both toxins 
can cause cell death by directly interacting with the mitochondria.  TcdA induces 
apoptosis by localizing at the mitochondria and disrupting this important organelle, 
an event that appears to occur prior to the glucosylation of Rho proteins (79).  
Recent studies by Matarrese, et al, found that TcdB also directly impacted the 
mitochondria by causing mitochondrial hyperpolarization.  Using isolated 
mitochondria, TcdB was also found to cause mitochondrial swelling and release of 
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cytochrome c, a pro-apoptotic factor (134).  Other investigations indicate that TcdB 
is capable of inducing caspase 3-dependent apoptosis as well as caspase-
independent apoptosis (164).  Interestingly, studies indicate that cell death does 
not occur until 24 h post-intoxication (164), well after changes in the actin 
cytoskeleton occur; however, most likely both the cytopathic and cytotoxic effects 
of the toxins are important contributors to the pathology of CDAD. 
 
TcdA and TcdB in disease 
TcdA and TcdB are the major virulence factors of C. difficile and are examples of 
toxins that alone can recapitulate many of the disease symptoms (210).  The toxin-
related effects on the actin cytoskeleton, tight junctions, and cell viability together 
with immunopathological events (most of which are toxin-mediated as well) illicit 
the typical pathology of C. difficile colitis:  massive inflammatory infiltration, 
damage to the intestinal mucosa, and fluid secretion (210).   
 
A hallmark of CDAD is an intense, acute inflammatory response in the intestines, 
which can be attributed both directly and indirectly to the toxins.  TcdA and TcdB 
have been shown to directly activate monocytes and stimulate the release of 
interleukin-8 and tumor necrosis factor-α (TNF-α) (120, 185).  Toxin-activated 
macrophages also release macrophage inflammatory protein 2 (MIP-2) and 
substance P, both of which have been shown to stimulate fluid secretion and 
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contribute to inflammation (29, 210).  In studies by Kelly et al, TcdA was shown to 
directly bind to neutrophils (103).  Interestingly, mice that are deficient in mast cells 
are less sensitive to TcdA and demonstrate a reduction in neutrophil recruitment 
and fluid accumulation (Wershil, 1998) and TcdA was also shown to cause the 
degranulation mast cells, which in turn produces TNF-α  (27).  All of these events 
contribute to the massive neutrophil recruitment, inflammation, and extravasations 
of the colon, a typical pathology of a CDAD patient.  
 
TcdA acts as an enterotoxin, causing a fluid accumulation within the colon.  
However, unlike the rice-water fluid induced by other enterotoxins, such as cholera 
toxin, TcdA induces hemorrhagic fluid production and substantial mucosal edema 
(126, 144, 159).  Also in contrast to cholera toxin, TcdA causes gross tissue 
damage by damaging the microvillus brush border, resulting in the shedding of 
cells into the lumen and the formation of shallow ulcers on the mucosa membrane 
(126, 144).  In addition to tissue damage, following luminal application of TcdA in 
rats, a release of substance P and calcitonin gene-related peptide occurred (160).  
Both of these peptides are implicated in the production of fluid and diarrhea (170). 
 
There are limited reports of TcdB effects on cells of the gastrointestinal tract, and, 
in general, TcdB has very little enterotoxic activity and is considered to be a potent 
cytotoxin (210).  Interestingly, TcdB was found to be only effective when given 
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intragastrically with low doses TcdA or when the intestines were mechanically 
damaged (127).  This suggests a synergy between TcdB and TcdA or perhaps 
other host-damaging C. difficile factors.  It also suggests that TcdA may facilitate 
the systemic release of TcdB.   
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CHAPTER III 
 
 
RATIONALE 
 
Because bacterial toxins are important contributors of disease, these virulence 
factors have been studied extensively over the last century.  While much is known 
about toxin mechanism of action and even toxin structure, the cells and organs 
targeted by many bacterial toxins during disease are unknown, leaving their 
overall impact on the host poorly understood.    Clostridium difficile toxin B (TcdB) 
is an example of a bacterial toxin studied extensively in vitro, but whose in vivo 
activities are poorly understood (210).  TcdB is a potent cytotoxin with a broad cell 
tropism and therefore is able to intoxicate a wide variety of cell types in vitro (16, 
38, 121, 137, 194, 217).  Yet, whether any of these cell types are impacted during 
disease is unknown.   
 
In general, Clostridium difficile-associated disease (CDAD) is a considered to be a 
disease of the gastrointestinal tract; however, in severe cases of CDAD, patients 
experience symptoms outside the colon (35, 44, 91, 138, 174). Furthermore, 
despite the theoretical eradication of the organism in the gastrointestinal tract via 
effective antibiotic therapy and complete colectomies, patients suffering with 
fulminate CDAD exhibit systemic damage outside of the gastrointestinal tract and 
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can still succumb to the disease, evidence suggestive of released soluble factors 
such as TcdB (78, 155).  Because circulating TcdB can be detected in serum and 
ascitic fluid, we hypothesize that TcdB could contribute to the systemic damage 
observed in patients with fulminate CDAD (166).  Therefore, in order to fully 
understand TcdB’s role in disease and design effective, toxin-specific CDAD 
therapeutics, it is necessary to determine the cell and organ tropism of TcdB in 
vivo.  Identifying systemic targets of TcdB (and other toxins) has been limited since 
it is difficult to directly visualize the impact of these proteins on major organs in 
real-time.   
 
To address this problem, zebrafish embryos are used herein to determine the in 
vivo targets of TcdB in real-time.  Unlike other vertebrates, zebrafish embryos are 
transparent and major organs can be visualized by standard light-microscopy 
(219).  Thus, zebrafish embryos provide a unique system for directly visualizing 
the effects of a TcdB intoxication event.  Additionally, experiments are performed 
using the established models of TcdB intoxication (mouse) and C. difficile infection 
(hamster), further confirming any results discovered in the zebrafish model.  The 
findings provide important insight into the in vivo activities of TcdB, and will present 
the zebrafish embryo as a model for determining the systemic targets of bacterial 
toxins. 
 57
CHAPTER IV 
 
IDENTIFICATION OF CLOSTRIDIUM DIFFICILE TCDB CARDIOTOXICITY 
USING A ZEBRAFISH EMBRYO MODEL OF INTOXICATION 
 
 
Identification of Clostridium difficile TcdB Cardiotoxicity Using a Zebrafish 
Embryo Model of Intoxication.  (Elaine E. Hamm, Daniel E. Voth, and Jimmy 
D. Ballard).  Proceedings of the National Academy of Sciences.  (2005). 
104:14176-81. 
 
Abstract 
Clostridium difficile TcdB has been studied extensively using cell-free systems and 
tissue culture; but, like many bacterial toxins, the in vivo targets of TcdB are 
unknown and have been difficult to elucidate with traditional animal models.  In the 
current study, the transparent Danio rerio (zebrafish) embryo was used as a model 
for imaging of in vivo TcdB localization and organ-specific damage in real-time.  At 
24 hours post treatment, TcdB was found to localize at the pericardial region, and 
zebrafish exhibited the first signs of cardiovascular damage, including a 90% 
reduction in systemic blood-flow and a 20% reduction in heart-rate.  Within 72 h of 
exposure to TcdB, the ventricle chamber of the heart became deformed and was 
unable to contract or pump blood, and the fish exhibited extensive pericardial 
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edema. In line with the observed defects in ventricle contraction, TcdB was found 
to directly disrupt coordinated contractility and rhythmicity in primary 
cardiomyocytes.   Furthermore, using a caspase-3 inhibitor we were able to block 
TcdB-related cardiovascular damage and prevent zebrafish death.  These findings 
present the first insight into the in vivo targets of C. difficile TcdB, as well as 
demonstrate the strength of the zebrafish embryo as a tractable model for 
identification of in vivo targets of bacterial toxins and evaluation of novel, 
candidate therapeutics.   
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Introduction 
 
Protein toxins are produced by bacterial pathogens during disease and have 
evolved different functions ranging from pore-formation in plasma membranes to 
enzymatic activities that alter intracellular signaling, cell cycle, apoptosis, and 
protein synthesis in targeted cells (178).  Mechanisms of receptor-binding, cell 
entry, membrane insertion, and enzymology are routinely determined using a 
broad range of cell types in vitro,  yet for many toxins the cell types targeted during 
disease are unknown (62).  
 
Clostridium difficile toxin B (TcdB) is an example of a bacterial toxin studied 
extensively in vitro, but the in vivo activities remain poorly understood (210).  TcdB 
is a potent (LD50= 200 ng/kg) intracellular bacterial toxin; the protein enters cells 
via receptor-mediated endocytosis, translocates to the cytosol, hydrolyzes UDP-
glucose, and transfers the liberated sugar to a reactive threonine in the effector 
binding loops of the small GTPases Rho, Rac, and Cdc42 (16, 55, 98, 99).  As a 
result, cultured cells treated with TcdB exhibit changes in cell morphology and 
undergo apoptosis, eventually leading to death of the cell (10, 17, 164).  TcdB 
intoxicates numerous cell types in vitro including fibroblasts, neuronal cells, 
epithelial cells, endothelial cells, lymphocytes, and hepatocytes (16, 38, 121, 137, 
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194, 217), yet whether any of these cell types are targeted during C. difficile 
associated disease (CDAD) is unknown. 
 
CDAD involves extensive gastrointestinal damage, however these pathologies 
appear to be caused by TcdA, a similar toxin encoded on the same pathogenicity 
locus as TcdB (46, 127).  This raises further questions about the role of TcdB in 
disease.  Previous studies have shown that TcdB is only effective when the 
intestinal mucosa is damaged (221), suggesting that the intestinal effects of TcdA 
facilitate the entry of TcdB into the bloodstream.  In life-threatening cases of 
CDAD, systemic complications include cardiopulmonary arrest (96), acute 
respiratory distress syndrome (91), multiple organ failure (44), renal failure (35), 
liver damage (174), and each could be due to the systemic effects of TcdB.  
Hence, identifying the cells targeted in vivo by TcdB is needed in order to gain 
relevant insight into the disease-related activities of this toxin, and advance our 
understanding of CDAD. 
 
Identifying systemic targets of bacterial toxins such as TcdB has been limited since 
it is difficult to directly visualize the impact of these proteins on major organs in 
real-time.  To overcome this problem, zebrafish embryos were used herein to 
characterize the systemic impact of TcdB in real-time.  Unlike other vertebrates, 
zebrafish embryos are transparent and major organs can be visualized by 
 61
standard light-microscopy (219).  Thus, zebrafish embryos provide a unique 
system for directly visualizing the temporal and spatial effects of TcdB intoxication.  
By using the zebrafish embyro as a model, in the current work we have found that 
TcdB functions as potent cardiotoxin, reducing blood-flow and ventricle 
contraction.  Furthermore, corresponding to TcdB’s known pro-apoptotic activity, a 
caspase-3 inhibitor was found to alleviate the cardiotoxic effects of TcdB.  These 
findings provide important insight into the in vivo activities of TcdB, and present the 
zebrafish embryo as a model for determining the systemic targets of bacterial 
toxins.  
Results 
Localizaton of TcdB in zebrafish embryos.  To determine the localization of TcdB, 
zebrafish were treated with fluorescently-labeled (Alexa-Fluor 546) TcdB 
(TcdBAlexa-546) approximately 48 hours post-fertilization (hpf) and examined by 
fluorescence microscopy for sites of toxin tropism.  As shown in Fig. 9, following a 
24 h treatment with the toxin, TcdBAlexa-546 localized at the frontal ventral portion of 
the fish, with specific foci formed within the pericardial region. Localization of 
TcdBAlexa-546 was also observed in an anatomical region corresponding to the 
outflow chamber of the heart (see arrow in Fig. 9A).  Magnified views, as shown in 
Fig. 9D and E, reveal intense localization near the cardiac region.  In contrast, the 
negative control, fluorescently-labeled bovine serum albumin (BSA) BSAAlexa-546, 
did not show detectable anatomical localization within the zebrafish (Fig. 9F-G).   
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Fig. 9.  TcdB localization observed in zebrafish.  (A)  Zebrafish (48 hpf) treated 
with 37 nM TcdBAlexa 546 for 24 h.  Arrows indicate toxin accumulation around the 
pericardial sac as well as distinct foci on the yolk sac and upper cranial region.  
(B)  Zebrafish treated with 37 nM TcdBAlexa 546 and 370 nM TcdB receptor binding 
domain (RBD).      (B) Exhibited a substantial decrease in fluorescence, indicating 
that that the RBD can competitively reduce TcdB binding and TcdB localization is 
specific. Images were acquired and processed using identical intensity and 
contrast settings for each sample. (C) Brightfield image of zebrafish treated with 
Zebrafish treated with 37 nM TcdBAlexa 546 and 370 nM TcdB receptor binding 
domain (RBD).  Arrow 1 points to the heart, arrow 2 indicates the gastrointestinal 
tract, and arrow three points to the eye  (D) Magnification of the pericardial region 
and (E) the yolk sac of a zebrafish treated with TcdBAlexa 546.  (F) Zebrafish treated 
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To further demonstrate specificity of TcdB localization, competition experiments 
were performed using the putative receptor binding domain (RBD) of TcdB.  As 
shown in Fig. 9B, co-treatment with 30 fold molar excess of the TcdB receptor 
binding domain reduced the detectable levels of labeled toxin to that observed in 
the BSA control. Collectively, these observations suggested TcdB exhibits specific 
tissue tropism in the zebrafish, with the toxin primarily localizing to the yolk-sac, 
pericardial, and cardiac region of the zebrafish.  
 
Treatment of zebrafish embryos with TcdB results in damage to the cardiovascular 
system.   Experiments were performed to determine the effects of TcdB on 
zebrafish physiology.  For initial analysis, zebrafish embryos were collected at 24 
hpf and exposed to TcdB, heat-inactivated TcdB, or buffer alone.   Treatment with 
doses ranging from 0.037 nM to 0.37 nM did not cause detectable damage to the 
zebrafish embryos (data not shown).  However, exposure of the embryos to doses 
of toxin ranging from 3.7 nM to 37 nM resulted in distinct, dose-dependent 
changes in zebrafish physiology and anatomy.  
 
The time-course and specific changes in physiology are summarized in Table 1.  A 
decrease in heart rate was the first physiological change observed; 72 ± 6 
beats/30s in the control compared to 57 ± 3 beats/30s in TcdB-treated fish (p < 
0.001).  Corresponding to the reduced heart rate, a visible reduction in blood flow  
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HPTa System/Organ Impactedb Observed Phenotype 
24 Cardiovascular Reduced blood flow 
Heart Decreased beats per minute and 
arrhythmia 
24-48 Heart 
 
 
 
Decrease in chamber contraction 
Elongated ventricle and atrium 
Changes in heart morphology 
Mild Pericardial edema 
48-72 Heart 
 
Arrhythmia  
Necrotic Ventricle and Atrium 
Ventricle unable to contract 
Severe pericardial edema 
Gastrointestinal Necrosis 
Liver Discoloration 
72-96 Heart Complete loss of morphology 
Atrium unable to contract 
Gastrointestinal Severe necrosis 
Epithelium Degeneration of the epithelium 
a.  48 hpf treated with 37 nM TcdB 
b. Observed by standard light microscopy at 100X magnification 
 
Table 1.  Summary of Temporal Systemic Effects of TcdB 
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(calculated as the red blood cell (RBC) perfusion rate) was also observed.  In 
control fish, RBC perfusion rate within the intersegmental veins was 402 ± 10.6 
RBC/30s at 24 h post-treatment.  In comparison, in TcdB-treated zebrafish, the 
RBC perfusion rate within intersegmental veins was 44 ± 1.49 RBC/30s (p < 
0.0001) (See Fig. 10 and supplemental Movie 1-2 on the PNAS web site).  
Reduced blood-flow was observed in the caudal and intersegmental veins, and 
appeared to occur in the absence of detectable damage to the vascular 
endothelium. To confirm this, fli1::EGFP zebrafish, which express GFP in 
endothelial cells, were utilized to assess vein integrity following treatment with 
TcdB.  As shown in Fig. 10B and C, despite a loss in blood flow, the veins of toxin-
treated zebrafish appeared to be intact.   
 
TcdB-treated zebrafish were examined for cardiac damage, as a possible 
explanation for the reduction in blood-flow.  Between 24-48 h post-treatment, there 
was a decrease in ventricle chamber contractility and loss in heart looping (see 
Fig. 11 and the supplemental Movies 3-4).  As shown in Fig. 11, in control fish, the 
ventricle exhibited a dynamic change in size of 20% during contraction and 
expansion (see supplemental Movie 3).  However, treatment with TcdB 
substantially reduced the change in ventricle size during beating (see Movie 13), 
indicating the heart was unable to contract and expand in a normal fashion.  At 
approximately 48 h post-treatment, both the atrium and ventricle were deformed  
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Fig. 10.  RBC perfusion rate and vein integrity of TcdB-treated zebrafish.  (A) 
Red blood cell perfusion (RBC) rate was used as a measurement of blood flow 
and calculated as the average # of RBC/30 s in the intersegmental veins (n=27) 
with error bars representing standard error. Zebrafish treated with TcdB had a 
reduced RBC rate compared to the heat-inactivated TcdB control.  Transgenic 
fli1::EGFP embryos were treated with TcdB and, after a loss of blood flow became 
apparent, were examined for changes in vein ultrastructure.  Images of veins of 
control heat-killed zebrafish (B) and veins of TcdB-treated zebrafish (C).  Images 
are viewed at 40X magnification using a Leica® confocal microscope and were 
processed using Leica® Confocal Software.      
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Fig. 11.  Comparisons of contraction and expansion dynamics of the 
ventricle in control-and TcdB-treated zebrafish embryos.   (A) Plot of relative 
changes in ventricle size in heat-inactivated TcdB (control) (black line) and TcdB-
treated (dashed line) embryos over at 10 s time-period.  TcdB-treated zebrafish 
had a marked decrease in overall ventricular size.  (B) Panels showing 
incremental contraction and expansion in control zebrafish embryos.  (C) Panels 
showing absence of contraction and expansion in TcdB-treated embryos.  
Ventricle is denoted in white. 
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(Fig. 12).  By 7 days post-treatment, 100% of TcdB-treated fish exhibited 
pericardial edema, with 70% developing whole-body edema (Fig. 13). TcdB-
treated fish survived between 7-10 days after initial exposure to TcdB, but by 11 
days post-treatment, 100% of the fish died. Similar cardiovascular defects were 
observed in fish treated with TcdB 24, 72, and 96 hpf, indicating that toxin effects 
were not dependent upon treatment at a particular stage of development (data not 
shown). Collectively, these observed defects indicated TcdB disrupts cardiac 
function. 
 
Delivery of the TcdB enzymatic domain with a surrogate system results in systemic 
damage.  Experiments were next performed to determine if the cardiotoxicity of 
TcdB was due to heightened sensitivity of this organ to the toxin’s enzymatic 
activity, or if this effect results from a preferential localization of the toxin to the 
heart.  Arguably, if TcdB cardiotoxicity were due to specific toxin tropism, then 
delivery of the enzymatic domain with a system that targets multiple tissues, 
should reduce these effects, as the enzymatic domain would be distributed 
throughout the body.  Alternatively, if cardiotoxicity were due to heightened 
sensitivity of cardiac tissue to the enzymatic activity of TcdB, then the heart should 
be preferentially impacted despite localization of the enzymatic domain to multiple 
tissues.  To address this issue we took advantage of a  
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Fig. 12.  Morphological changes in zebrafish heart following exposure to 
TcdB.  (A) Zebrafish embryos treated with 37 nM heat-inactivated TcdB at 37 hpf.  
(B)  Zebrafish embryos (37 hpf) treated with 37 nM TcdB at 37 hpf (n=50).  
Images are of live embryo hearts at 48 h post treatment.  A=Atrium, V=Ventricle 
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Fig. 13.  Representative photographs of zebrafish following exposure to 
TcdB.  (A)  Control zebrafish treated heat-inactivated TcdB (37 nM). (B) Defects 
observed in cleavage stage-treated fish 144 h post treatment treated with 37 nM 
TcdB (n=50).  Arrows indicate regions of massive edema observed following 
cardiac damage.  
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previously described heterologous delivery system derived from the cell entry 
components of anthrax lethal toxin, which consists of Bacillus anthracis protective 
antigen (PA) and LFnTcdB1-556, a fusion protein consisting of the translocation 
active, non-toxic 255 amino-terminal residues of anthrax toxin lethal factor (LFn) 
and the enzymatic glucosylation region of TcdB (amino acids 1-556) (4, 142, 186). 
Previous studies have shown that PA can target multiple tissues within the 
zebrafish (197, 211). As shown in Fig. 14, zebrafish embryos treated with PA and 
LFnTcdB1-556 exhibited widespread tissue damage, which differed substantially 
from that observed in TcdB-treated zebrafish.  These findings suggest that TcdB-
related cardiac damage may involve a specific tropism for cardiac tissue. 
 
TcdB modulates cardiomyocyte physiology.   Results from the zebrafish treatments 
indicated that TcdB could influence cardiac function, perhaps by directly targeting 
functional cells of the heart.  To further elucidate TcdB-cardiotoxic effects, 
experiments next sought to determine if this toxin were capable of disrupting the 
physiology of cardiomyocytes.  In these experiments, cultured cardiomyocytes 
were treated with TcdB and examined for changes in overall morphology, 
contraction, and viability.  Within two hours of toxin treatment, the cardiomyocytes 
exhibited morphological changes.  Phalloidin staining of actin in TcdB-treated 
cardiomyocytes revealed distinct changes in cellular structure when  
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Fig. 14.    Representative photographs of zebrafish following exposure to 
LFn-TcdB1-556.  (A) Zebrafish treated with LFn-TcdB1-556 alone resembled 
untreated zebrafish.  (B)  Zebrafish treated with PA and LFn-TcdB1-556 (n=50).  
Arrow indicates tissue damage (visualized as tissue discoloration). 
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Fig. 15.    TcdB intoxicates cultured primary rat cardiomyocytes (RCm).  (A)  
Rhodamine phalloidin actin stain of RCm treated with heat-inactivated TcdB (7.4 
nM). (B) RCm treated with TcdB (7.4 nM) and stained for actin 4 hpt.  (C)  
Changes in the number of contractions over time were also explored.  Heat-
inactivated TcdB-treated is represented by the solid, black line while TcdB-treated 
RCm is denoted by the dashed line. Contractions were measured 4 h post 
treatment as number of contractions per 60 s. 
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compared to cardiomyocytes treated with heat-inactivated TcdB (Fig. 15A and B).    
Control cells had numerous dense bodies of fibrils and bundled Z-bands (Fig. 
15A), while these structures were undetectable in cardiomyocytes treated with 
TcdB (Fig. 15B).   By 5 h post-treatment, the cardiomyocyte contractions were less 
coordinated and arrhythmic (Fig. 15C, see supplemental Movie 5-6).  Finally, 48 h 
post-treatment, there was a 60% decline in cardiomyocyte viability (data not 
shown).  
 
Caspase-3 inhibitor reduces cardiovascular damage in TcdB-treated zebrafish.  
TcdB is known to cause cytotoxicity via apoptosis, and blocking caspase activity in 
cell culture slows the rate of death following treatment with TcdB (164).  Hence, 
experiments were designed to determine if cardiotoxicity correlates with the ability 
of TcdB to induce apoptosis, and whether inhibition of apoptosis could provide 
protection against the systemic effects of this toxin.   In these experiments, 
zebrafish embryos were treated with TcdB and co-treated with Ac-DMQD-CHO, a 
water-soluble tetrapeptide inhibitor of caspase-3.  TcdB-treated and control 
zebrafish were observed for changes in heartbeat and overall blood flow.  As 
shown in table 2 zebrafish treated with TcdB exhibited a significant decrease in 
heartbeats/30s as compared to the control; yet, zebrafish co-treated with caspase-
3 inhibitor presented heart rates similar to control zebrafish along with a normal 
RBC perfusion rate (Fig. 16). The events quantified  
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Fig. 16.    Caspase-3 Inhibitor reduces the cardiotoxic effects of TcdB.  
Following concomitant exposure to TcdB and caspase-3 inhibitor, zebrafish were 
examined for reduction of TcdB-related phenotype, specifically decrease in heart 
function.  The RBC perfusion rate of treated zebrafish over time (stripped bar = 
heat-inactivated TcdB, white bar = caspase-3 inhibitor IV, black bar = TcdB, and 
dark grey = TcdB + caspase-3 inhibitor IV.  RBC perfusion rate is calculated as 
the average # of RBC/30 s in the intersegmental veins (n=27) with error bars 
representing standard error. 
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Treatment Heartbeat per 30 s, 72 h after 
treatment 
 (± standard deviation) 
 
Heat-inactivated TcdB 72 ± 6 
Caspase-3 inhibitor 76 ± 7 
TcdB 57 ± 3 
TcdB + caspase-3 
inhibitor 
78 ± 2 
 
 
Table 2.  Heart rate of treated zebrafish
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in Fig. 15 can be viewed as video (see Movie 7) in the supplementary material on 
the PNAS web site.  Furthermore, the addition of caspase-3 inhibitor decreased 
the frequency and severity of damage observed in the TcdB-treated zebrafish (Fig. 
16 and 17). These results indicate the cardiotoxic effects of TcdB can be alleviated 
by a caspase-3 inhibitor. 
 
Discussion 
 
Tissue damage and inactivation of specific cell-types by bacterial toxins is an 
integral part of many infections and is important for colonization, immune evasion, 
and progression of disease.  Thus, toxin immunogenicity and mechanisms of 
action have been studied for over a century, leading to new vaccines and an 
understanding of these virulence factors at the molecular level.  Yet, despite 
numerous advances in the study of bacterial toxins, little is known about cell types 
targeted in vivo (62).  In particular, and important to the current study, although C. 
difficile TcdB is a potent cytotoxin, has a low LD50, and causes rapid death in 
animal models, the overall physiological systems impacted by this toxin have not 
been identified.  
 
While in vitro studies have provided important insight into TcdB’s mechanisms of 
cell entry, membrane translocation, and enzymatic activity, it is difficult to apply  
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Fig. 17.  Caspase-3 inhibitor prevents TcdB-related damage in zebrafish.  
Zebrafish embryos were exposed to heat-inactivated TcdB, TcdB, or TcdB plus a 
caspase-3 inhibitor 72 hpf.   Approximately, 12 h post-treatment, zebrafish were 
observed for changes in morphology.  (A)  Zebrafish treated with a high dose of 
heat-inactivated TcdB resembled untreated zebrafish.  (B)  Zebrafish exposed to 
a high dose of TcdB demonstrated massive tissue degeneration while (C) 
zebrafish treated with TcdB and caspase-3 inhibitor resembled control zebrafish. 
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this knowledge to the in vivo setting.  In vitro analysis cannot mimic toxin receptor 
availability within the host nor reflect overall organ sensitivity to TcdB.  Therefore, 
in order to characterize TcdB’s systemic effects, we sought an animal model that 
would allow direct, in vivo visualization of events leading to death following 
exposure to the toxin.  Contemporary models, such as higher order primates, 
rodents (23), Drosophila melanogaster (37, 43, 129), and Caenorhabditis elegans 
(1, 50) were considered for assessing the systemic effects of TcdB, but these 
lacked many of the qualities needed for the current study.   It is difficult to directly 
visualize all the major organs in higher order models, and the fruit-fly and 
nematode systems lack the organ complexity needed for a thorough study of 
systemic damage.  In contrast, the zebrafish embryo provides several distinct 
advantages over these traditional models. In addition to having many of the major 
organs found in humans, zebrafish embryos are transparent, which allows direct 
visualization of labeled toxin and toxin-induced changes in anatomy and 
physiology (219).  Indeed, these same characteristics have made the zebrafish a 
widely accepted model for the study of embryonic development and genetics (73) 
and infectious diseases (39, 141, 150, 162, 163, 203, 204).  
 
The phenotypes of TcdB-treated zebrafish support the notion that intoxication with 
TcdB leads to cardiovascular damage.  Indeed, many of the changes observed in 
the TcdB-treated embryos have been reported in mutant lines of zebrafish 
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defective in genes necessary for a functional heart.  For example, dead beat 
(ded)(171, 187) and heartstrings (hst)(64) are documented to possess cardiac 
defects that result in poor contractility and pericardial edema (ded) or stretching 
and loss of function of cardiac chambers as well as a loss in circulation (hst).  
These phenotypes were observed in the TcdB-treated embryos, further suggesting 
that the toxin impacts cardiac function.  Additionally, results from the toxin 
localization experiments using TcdB labeled with a trackable marker, and the 
delivery of the TcdB enzymatic domain with PA and LFn, support the idea that the 
toxin preferentially localizes to the heart.  A specific in vivo affinity for cardiac 
tissue may explain why TcdB can damage many cell types in vitro, but primarily 
impacts the heart in the zebrafish. 
    
In the zebrafish embryo studies, loss in chamber contractility was observed, 
allowing for the identification of a relevant candidate cell type, cardiomyocytes, for 
further studies in cell culture.  Whether cardiomyocytes are the only cardiac cells 
impacted by TcdB is not known; however, loss of cardiomyocytes will have the 
most dramatic impact on the heart and may provide an explanation for TcdB-
related defects in contractility.  These cells are central to heart contraction and the 
movement of blood, thus even subtle intoxication events could have dramatic 
effects.  Furthermore, unlike cardiac fibroblasts and endothelial cells, 
cardiomyocytes are not renewable, and loss of these cells can result in chronic 
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heart problems (89, 128).  It seems reasonable to predict that if other cells are 
impacted by TcdB within the heart, death of cardiomyocytes would have a more 
severe and sustained effect on the host. 
 
In cardiac diseases that involve activation of apoptosis in cardiomyocytes, 
caspase inhibitors have been promoted as promising treatments (85, 86, 227). 
Moreover, prior work has shown that inhibitors of apoptosis, caspase inhibitors in 
particular, reduce the cytotoxic effects of TcdB (164).  Thus, it was hypothesized 
that inhibition of caspase-3 would alleviate the cardiac damage caused by this 
toxin.  The results of our study show that TcdB’s damaging and fatal cardiotoxic 
effects could be prevented through the use of a caspase-3 inhibitor.   To our 
knowledge, this is the first example in which a caspase inhibitor blocked in vivo 
effects of a bacterial exotoxin.  Moreover, these results suggest these compounds 
and other modulators of apoptosis could be promising therapeutics for treating 
advanced CDAD. 
 
It is important to consider the current findings in the context of CDAD in humans.  
Cardiotoxicity could explain many of the observed clinical signs of serious CDAD.  
Patients with advanced CDAD experience multi-organ failure, and decreases in 
cardiac function could be one of the factors contributing to this event (44).  Death 
of CDAD patient has also been directly associated with cardiac arrest (21, 96, 182, 
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199).  Collectively, these data suggest that inactivation of Rho, Rac, and Cdc42, by 
TcdB leads to altered cardiac activity and cell death in the heart of CDAD patients.  
Ongoing studies assessing cardiac damage in infectious models of CDAD will help 
in directly addressing this hypothesis. 
 
In summary, results from the current study now provide insight into a possible 
mechanism by which C. difficile causes severe systemic damage during CDAD.  
By functioning as a cardiotoxin, TcdB may directly or indirectly cause much of the 
systemic damage observed in CDAD patients. These findings also indicate that the 
zebrafish embryo is a valuable model for identifying systemic targets of bacterial 
virulence factors and that this model is useful in the in vivo assessment of toxin 
therapeutics.  
 
Materials and Methods 
 
Protein isolation.  TcdB was isolated as previously described (165). Bacillus 
anthracis protective antigen (PA) and LFnTcdB1-556 were isolated as previously 
described (4, 142, 186).  The 2165 nucleotides from the 3’ end of the tcdb gene, 
which encode for the putative receptor binding domain (RBD) of TcdB, were cloned 
in-frame into the pET15b plasmid (Novagen).  All recombinant proteins were 
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expressed as a His6 fusion in Escherichia coli/BL-21 DE3 and isolated using Ni2+ 
affinity chromatography according to the manufacturer’s protocol (Novagen).    
 
Fluorescent labeling of protein.  TcdB and BSA were labeled with a reactive 
fluorescent dye Alexa-Fluor546, according to manufacturer’s instructions (Molecular 
Probes, Invitrogen).  The relative activity of labeled TcdB to unlabeled TcdB was 
determined using a standard cytoxicity assay.  Labeling of TcdB did not reduce the 
effective cytotoxic dose of the toxin by more than 20%.   
 
Zebrafish maintenance and care.  Wild-type zebrafish were obtained from Aquatic 
Eco-system (Apopka, FL) and mutant fli1::EGFP fish were obtained from ZFIN 
(University of Oregon, Eugene, Oregon).  Zebrafish were maintained at 28.5ºC on 
a 14 h light/10 h dark cycle in a Z-plex unit (Aquatic Habitats) and matings, 
embryro collection, and preparation were performed as previously described  
(219).  
 
In vivo toxin localization studies using fluorescently labeled TcdB.  Zebrafish 
embryos were placed into a 96-well plate (5 embryos/well) 24 h post fertilization 
(hpf) and allowed to incubate with TcdBAlexa 546 (3.7 nM-100 nM) or TcdB Alexa 546 (3.7 
nM-100 nM) and 30 fold molar excess TcdB RBD for 24 h.  Control zebrafish were 
incubated with 100 nM BSAAlexa 546.  Subsequently, zebrafish were rinsed 10 times 
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in embryo water for 20 min and visualized using an Olympus BX81 epifluorescent 
microscope.  Images were captured and processed using the Nikon Spot 
Software.  
 
Treatment of zebrafish embryos with TcdB and LFnTcdB1-556.  For TcdB studies, 
zebrafish embryos were placed (5 embryos/well) into a 96-well plate and treated 
with 37 nM of TcdB, heat-inactivated TcdB, or 20 mM Tris-HCl buffer in replicates 
of 10 (50 embryo/experimental condition). Similarly, LFnTcdB1-556–treated 
zebrafish were placed (5 embryos/well) into a 96-well plate and treated with 0.42-
0.85 nM PA and LFnTcdB1-556 in replicates of 10 (50 embryos/treatment).  Controls 
included 0.85 nM PA or LFnTcdB1-556 and 20 mM Tris-HCl.  The embryos were 
observed for seven days post-treatment for morphological changes using a SZX-7 
microscope with a DP70 camera (Nikon).  All still and video images were captured 
and processed using the DP controller and DP manager software (Nikon).  To 
calculate blood circulation, the red blood cell (RBC) perfusion rate was measured 
using the SZX-7 Nikon microscope with a DP70 video camera and is recorded as 
the number of blood cells detected within the intersegmental veins over a 30 s 
time period.  RBC perfusion rate was measured in replicate countings in three 
separate veins in three separate fish and is reported as # of RBC/30 s.  
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Treatment of rat cardiomyocytes with TcdB.  Primary rat cardiomyocytes (RCm) 
cells (Cell Application) were seeded into 96-well plates and treated in triplicate with 
7.4 nM TcdB or heat-inactivated TcdB for five hours, and subsequently stained with 
rhodamine phalloidin according to the manufacturer’s instructions (Molecular 
Probes, Invitrogen).  Images were acquired using a TCS NT confocal microscope 
(Leica) and processed using Confocal Software (Leica).   RCm cell viability post-
TcdB treatment was quantified across a 72 h time-period using the Cell Counting 
Kit-8 (CCK-8, Dojindo). 
 
Caspase-3 inhibitor assays.  Zebrafish embryos were placed into a 96-well plate 
(at 5 embryos/well) in sterile embryo water and were treated concomitantly with 
TcdB (37 nM) and caspase-3 inhibitor IV (Calbiochem) (500 μM) and were 
observed up to one week post-treatment.  Controls for this experiment included 
500 μM caspase-3 inhibitor IV, TcdB (37 nM), and heat-inactivated TcdB (37 nM). 
The embryos were examined for changes in heart rate and RBC perfusion rate, as 
well as phenotype using SZX-7 Nikon microscope with a DP70 camera.  All still 
and video images were captured and processed using the DP controller and 
manager software.  
 
Statistical analysis of data.  All statistical data was calculated using a Student’s 2 
tailed t-Test.   
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CHAPTER V 
 
ELUCIDATING THE CARDIC DAMAGE OF FULMINATE CLOSTRIDIUM 
DIFFICILE-ASSOCIATED DISEASE:  CONSIDERATIONS BEYOND THE 
GASTROINTESTINAL TRACT 
 
Abstract 
Clostridium difficile is the etiological agent of Clostridium difficile-associated 
disease (CDAD).  This disease is primarily confined to the colon; however, patients 
with fulminant disease exhibit signs of severe systemic damage in addition to 
damage to the gastrointestinal tract.  Because previous studies indicate that C. 
difficile’s exotoxin, TcdB, can act as a potent cardiotoxin, the current study 
investigates the potential cardiac damage from a TcdB intoxication event and C. 
difficile infection in rodents and in human patients.  Results from rodent studies 
reveal that systemic TcdB intoxication event and infection with C. difficile cause 
massive myocardial infarct as well as edema, hemorrhaging, and marked vein 
dilation in the examined heart tissue.  In addition, in a preliminary, retroactive 
review of patient autopsy data revealed that patients who died with CDAD also 
demonstrated massive damage to heart tissue with edema, hemorrhaging, 
lymphocytic infiltrates, and damage to myocardial fibers, similar to what was 
observed in the rodent disease models.  In total, data from the current 
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investigation indicate that CDAD in animals and humans may result in severe 
damage to the heart.  
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Introduction 
Clostridium difficile-associated disease (CDAD) impacts 250,000-1,000,000 people 
annually in the United States, making C. difficile a significant cause of infectious 
disease (222).  Unfortunately, the number of cases of CDAD has increase in the 
past few years, with the US Nosocomial Infection Surveillance System reporting a 
twice the number of cases of CDAD since 1986 (2).  More concerning is the 
increase in morbidity and mortality associated with CDAD.  In one hospital setting, 
the mortality rate of CDAD patients increased from 3.5% to 15.3% from 1994-2000 
(147), while in hospices the mortality rate has now approached 25% (41).  The 
increase in cases, morbidity, and mortality of CDAD can be attributed, in part, to 
the emergence of hypervirulent strains of C. difficile that produce high levels of 
toxin and have more resistance to clindamycin and fluoroquinolines (97).   
 
CDAD symptoms of this disease range from the mild, with self-limiting diarrhea 
and abdominal cramping, to the severe; with development of pseudomembranous 
colitis, paralytic colon, and toxic megacolon.  While the etiology of the colonic 
disease has been well-studied, little is known about the cause of systemic 
complications in severe CDAD, making it difficult to treat patients with fulminant 
disease.  Although in general CDAD is a disease confined to the gastrointestinal 
system, patients suffering from life-threatening cases of CDAD exhibit signs of 
damage outside of the colon (35, 44, 91, 96, 174).  Additionally, in some cases, a 
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fatal outcome occurs despite total colectomy and eradication of the organism (78, 
155); further suggesting systemic effects of C. difficile or soluble virulence factors 
released from this bacterium.     
 
The major virulence factors of C. difficile and the main contributors to CDAD 
symptoms and pathology are its toxins, toxin A (TcdA) and toxin B (TcdB) (125).  
Because toxin has been detected in serum and ascitic fluid of CDAD patients and 
patients develop serum antibodies to the toxins, it is possible that circulating toxins 
may contribute to the systemic complications in severe CDAD (166, 206, 215). 
Previous studies, also featured in Chapter IV of this dissertation, determined that 
TcdB localizes to the pericardial region and causes a disruption in cardiac function, 
resulting in decrease in chamber contraction, loss in blood flow, cardiac tissue 
damage, and death of zebrafish embryos (75).  Results from this investigation 
indicate that TcdB is a potent cardiotoxin capable of reducing heart contraction and 
hindering blood-flow.   Further studies using cardiomyocytes revealed that TcdB 
altered cell physiology and disrupted coordinated cellular contractions.  
Collectively, these and previous findings, suggest more insidious, systemic events 
outside of the gastrointestinal tract (notably heart damage) as a cause for patient 
morbidity and mortality.  
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In order to further investigate the potential cardiac damage in CDAD and confirm 
findings in the zebrafish model, we sought to analyze the effects of a systemic 
TcdB intoxication event and C. difficile infection using rodent models and collected 
CDAD patient data.  Corresponding to the cardiac damage in the zebrafish model, 
both mice intoxicated with TcdB and hamsters infected with C. difficile exhibited 
signs of massive cardiac damage including damaged myocardial cells and 
myocardial fibers, edema, hemorrhaging, vein dilation, blocked blood vessels, and 
lymphocytic infiltration (Fig. 22 and 23, respectively).  In order to relate these 
findings to human disease cardiac, histopathology was obtained from patients who 
died with CDAD and examined for signs of tissue damage in a preliminary, 
retroactive study.  Importantly, in this initial investigation, patients who died with 
CDAD demonstrated signs of severe cardiac damage similar to that of our animal 
models with damage to myocardial tissue, edema, hemorrhaging, and lymphocytic 
infiltration (Fig. 24).  These findings present the first comprehensive investigation 
into the systemic events in fulminant CDAD and confirm one of the main organ 
targets of the major virulence factor, TcdB.   
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Results 
 
The cardiac tissue of mice intoxicated with TcdB revealed signs of cardiac 
damage.  Mice were injected with a dose range of TcdB intravenously and 
following their death, their organs were examined via histopathology.  Treatment 
with lethal (>50 ng) and sublethal doses of toxin resulted in damage to cardiac 
tissue.  The pathology revealed signs of myocardial infarct (Fig 18), damaged 
myocardial cells, edema, hemorrhaging, and lymphocytic infiltrates.  Mice treated 
with lethal doses of TcdB exhibited minimal signs of morbidity prior to death. 
 
Hamsters infected with C. difficile demonstrated detectable damage to heart 
tissue.  Hamsters were infected with 104 C. difficile and examined for signs of 
cardiac damage.  Approximately 36-48 hours post infection, hamsters 
demonstrated few signs of morbidity, produced minimal diarrhea (appearing as 
“wet tail”), and then died quietly (no signs of distress or convulsions).  
Immediately, following disease-related death, heart tissue was collected and 
examined via histopathology.  Compared to control hamsters, the cardiac tissue 
of hamsters with CDAD revealed cardiac damage including damage to 
myocardial fibers (as visualized as loss of striations in myocardial fibers), 
hemorrhaging, edema, and lymphocytic infiltrates (Fig 19).      
 
Patients that presented with CDAD upon death exhibited signs of cardiac 
damage.  Following animal studies with TcdB and C. difficile, hearts from patients 
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with CDAD were examined.  In this initial, retrospective study, cardiac tissue was 
obtained via autopsy from 5 patients that died with CDAD, and were analyzed for 
signs of cardiac tissue damage via histopathology.   Although in addition to CDAD 
these patients had varying pre-existing conditions, they all demonstrated similar 
signs of cardiac damage including damage to heart tissue, hemorrhaging, 
edema, and lymphocytic infiltrates (Fig. 20).   
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Fig. 18.  Representative heart tissue following systemic intoxication with 
TcdB.  Mice were injected intravenously with buffer control or TcdB and their 
heart tissue was examined for signs of damage via histopathology.   Compared to 
control mice (left panels), mice injected with TcdB (right panel) demonstrated 
signs of massive myocardial infarct:  damaged myocardial cells (arrow 1), edema 
(arrow 2), lymphocytic infiltrates (arrow 3), and hemorrhaging and capillary 
congestion (arrow 4). 
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Fig. 19.  Representative heart tissue from hamsters with CDAD.  Hamsters 
were infected with buffer control or TcdB and, following disease-related death, 
heart tissue was examined for signs of damage via histopathology.   Compared to 
control hamsters (left panels), hamsters with CDAD (right panel) demonstrated 
signs of massive heart damage:  loss in striated myocardial fibers (arrow 1) and 
vein dilation (arrow 2). 
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Fig. 20.  Representative heart tissue of patient with CDAD.  In a retroactive 
study, patients that died with CDAD were examined for signs of damage via 
histopathology.   Cadaver heart tissue demonstrated signs of heart damage:  
hemorrhaging (arrow 1), lymphocytic infiltrates (arrow 2), and edema (arrow 3). 
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Discussion 
 
C. difficile is one of the leading causes of hospital-associated disease and is the 
primary cause of antibiotic-associated diarrhea (210).  The pathogenesis of C. 
difficile within the intestines has been extensively studied, and several events are 
known to contribute to the inflammation and pseudomembrane formation (125, 
210).  Of particular importance is the release of two exotoxins, which contribute 
to the pathologies observed in CDAD.  The two major C. difficile toxins are TcdA 
and TcdB, which share similar mechanisms of action but differ in their ability to 
cause disease.  In general, TcdA, with its limited cell tropism and in vivo 
enterotoxic activity, is considered to be the enterotoxin, while TcdB, possessing a 
very broad cell tropism and limited enterotoxic activity is considered to be a 
potent cytotoxin (6, 192).  Results from several studies indicate TcdA contributes 
to intestinal damage and modulates the extensive inflammatory response 
observed in CDAD patients, while, the vast majority of the reports implicate TcdB 
as a cytotoxin and a potential contributor of the systemic events during fulminant 
disease (6, 125, 192, 210) .   
  
Although the cellular and physiological events leading to intestinal pathology in 
CDAD patients have been defined, little is known about the systemic events in 
these patients.  However, in life-threatening cases of CDAD, major organs are 
impacted.  Acute respiratory distress syndrome (91), multiple organ failure (44), 
cardiopulmonary arrest (96), chronic renal failure (35), as well as liver abscesses 
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(174) have all been described in CDAD.  Sepsis does not appear to be the likely 
cause of death in fulminant CDAD.  In a thorough literature review and personal 
communication (Stuart Johnson MD and Dale Gerding MD Hines VA, Chicago, 
IL), C. difficile is rarely cultured from the blood of patients (52)  and, in laboratory 
studies, blood from hamsters infected with C. difficile (unpublished data) are 
culture negative.   These data, coupled with the low incidence of C. difficile in the 
bloodstream (personal communication with Stuart Johnson and Dale Gerding, 
MD VA hospital, Chicago), indicates that systemic events may be due to the 
release of bacterial toxins into the bloodstream and not sepsis.  Furthermore, in 
some cases, a fatal outcome occurs despite total colectomy and eradication of 
the organism via antibiotic therapy (78, 155) and in one report, death generally 
occurred prior to colon perforation and was a rare event (2/64 patients) (36).  
These data indicate that systemic events may be due to the release of bacterial 
toxins into the bloodstream and not sepsis.    
  
It has been reported previously and in this dissertation that in zebrafish, TcdB 
localizes to the pericardial region and causes cardiac damage including reduction 
in chamber contractility and degeneration of heart tissue as well as loss in blood 
flow resulting from the potential disruption of cardiomyocyte physiology and cell 
death (75).  Consistent with this report, results from the current study indicate 
that in higher order animals and patients with CDAD all demonstrate signs of 
cardiac damage.  Mice systemically intoxicated with TcdB demonstrated no signs 
of severe morbidity prior to death, yet necropsy revealed signs of acute 
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myocardial infarct and hemorrhaging and edema within the heart, suggesting 
heart failure as a potential cause of death.  Similarly, hamsters with a C. difficile 
infection within the colon also demonstrated minimal signs of distress and 
minimal diarrhea TcdB also results in severe cardiac damage, also suggestive of 
insidious, systemic events involving the heart.  In three separate animal models 
systemic intoxication and infection with C. difficile resulted in damage to cardiac 
tissue, thus leading us to investigate the potential heart damage in humans with 
CDAD.  In a retrospective histopathological examination of patient autopsy data, 
heart tissue from patients who died with CDAD also revealed demonstrated 
substantial damage similar to that observed in the animal models.  Although due 
to the nature of this initial analysis, it is difficult to discern whether this damage 
can be directly attributed to TcdB, the preliminary human pathology further 
indicates that systemic, cardiotoxic events outside of the gastrointestinal tract can 
occur in patients with severe CDAD. 
 
CDAD is a complex disease with both colonic and systemic etiologies.  However, 
the systemic events of this disease are not well-understood.  Yet, clearly, 
extracolonic activities can be the major contributors to patient morbidity and 
mortality.    Thus, understanding the systemic events is necessary so that more 
comprehensive treatments can be established, especially in light of the 
association of this disease with antibiotic therapy and antibiotic resistant strains.  
Treatment approaches must therefore extend beyond antibiotic regiments and 
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certainly beyond the colon in order to treat the short term and potentially long 
term effects of this increasingly fatal disease 
 
Materials and Methods 
 
Purification of TcdB. TcdB was isolated as previously described (165).  Briefly, C. 
difficile VPI 10463 was grown in dialysis tubing suspended in brain heart infusion 
broth (BHI) and grown at 37°C for 72 h.   The culture was then centrifuged and 
TcdB was purified from the collected supernatant using sequential 
chromatography steps including anion-exchange (Q-Sepharose) chromatography 
and high resolution anion-exchange (Mono-Q) chromatography.  TcdB was de-
salted into 20 mM Tris-HCl, pH 8.0 and the protein concentration was determined 
via the Bradford method (20). 
 
Spore preparation.  For spore preparation, C. difficile VPI 10463 was grown in 
sporulation broth (For 1 L, 90 g Trypticase Peptone, 5.0 g Proteose Peptone, 1.0 
g (NH4)2 SO4, 1.5 g Tris to 1000 ml H2O, pH= 7.4) (223) in hanging dialysis 
tubing for  2 weeks.  Spores were centrifuged and washed in deionized H2O, and 
heat-inactivated via incubation at 72°C for 20 min.  Following heat-inactivation, 
spores were washed twice in cold, deionized H2O, and incubated at 16°C, 
shaking at 300 rpm for 72 h.  Spores were washed in cold, deionized H2O until 
vegetative cells and debris was removed and the final spore sample was filtered 
through a 3.1 mm filter.  Spore purity was determined via the Wirtz-Conklin spore 
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stain and spores were collected at no less than 90% purity.  Following spore 
preparation, spores were innumerated on BHI agar plates (37°C, anaerobic 
conditions) and reported as colony-forming units (CFU).    
 
Mouse intoxication studies.  For TcdB intoxication experiments, 6 week BALB-c 
mice (Charles River) were injected intravenously with TcdB (1.0 ng-1.0 μg). 
Controls were injected with 20 mM Tris-HCl buffer.  Immediately following death, 
organs were collected in 10% buffered formalin and processed for pathology.  
Mice injected with sublethal doses of TcdB (<50 ng) (10 ng and 20 ng), were 
euthanized 72 h post-intoxication via CO2 asphyxiation and organs were 
immediately harvested and processed for pathology. 
 
Hamster infection studies.  Male Golden Syrian hamsters (Charles River) were 
injected intraperitoneally with clindamycin (30 mg/kg) (Sigma).  Two days post-
antibiotic therapy, hamsters were orally administered 104 C. difficile spores via 
gavage needle.  Immediately following death, organs were collected in 10% 
neutral buffered formalin and processed for pathology. 
 
Mouse and hamster histopathology.  Tissues were fixed in 10% neutral buffered 
formalin, embedded in paraffin, and sectioned at 5 μm for routine staining.  
Sections were deparaffinized and rehydrated through three changes of xylene 
and graded alcohol and stained with hematoxylin and eosin.  Slides were 
coverslipped and examined for histopathology.  This portion of the experiment 
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was performed in collaboration with Ms. Megan Lerner, research associate in the 
pathology department of the VA hospital in Oklahoma City, Oklahoma.      
 
Human autopsy pathology. Pathology was performed on cadaver tissue from 
patients who all presented with CDAD upon autopsy.  This retroactive 
investigation was carried out as part of a collaborative effort with Dr. Stan 
Lightfoot.  Credit for this preliminary investigation should be given solely to Dr. 
Stan Lighfoot, Dr. Brandon Guthrey, and Ms. Megan Lerner.   
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CHAPTER VI 
 
SUMMARY 
The goal of the studies presented herein is to further understand the role of a 
bacterial toxin during the disease process.  In 1888, researchers Emile Roux and 
Alexandre Yersin demonstrated that the systemic symptoms of diphtheria could 
be recapitulated using cell-free filtrates; an observation that lead to the discovery 
of diphtheria toxin and the beginning of bacterial toxin research (172).  Since that 
seminal study, the mechanism of action and even the structures of most bacterial 
toxins have been elucidated.  However, despite advancements in the field of 
toxin research, the organs targeted by many bacterial toxins during disease are 
unknown, leaving the overall impact of these major virulence factors on the host 
poorly understood.   The purpose of this research was to develop a new 
animal model that enabled the determination of in vivo targets of bacterial 
toxins and to specifically investigate the targeted organs of one of the 
major toxins from C. difficile, TcdB.   
 
Although traditional animal modes have provided a wealth of information in toxin 
research, they have also presented numerous obstacles.  However, the zebrafish 
embryo model provides a solution to many of these major issues.  Besides the 
obvious appeal of the zebrafish embryo (size, population number, expense, care, 
and maintenance), the zebrafish embryo transparency circumvents the inherent 
problems with post-mortem analysis of tissue and organ damage.  By taking 
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advantage of this unique characteristic, researchers can intoxicate the animal 
and then, using simple light microscopy, determine which cell types are damaged 
in real-time and not following animal death.  Other experiments using labeled 
toxin can easily be performed to determine the anatomical localization of toxin in 
vivo, an appealing advantage over traditional models.  Therefore, if damage to 
the liver was observed histopathologically but only showed localization to the 
heart, this information could be used to ascertain the direct and indirect effects of 
the toxin.  Additionally, because the immune system of zebrafish develops at 
distinct time points, intoxication of the animal can be performed in the absence of 
an active and fully developed immune system, thereby negating the issue of 
nontoxin-related tissue damage due to an inflammatory response.  Overall, the 
transparent zebrafish embryo model allows for the direct visualization of toxin 
localization and activity and helps distinguish between toxin-related damage and 
secondary damage (i.e., post-mortem necrosis and inflammation).  By exploiting 
a simple fish commonly found in pet stores, a new animal model has emerged to 
investigate the in vivo effects of bacterial toxins.   
 
Chapter IV describes the development and the use of the zebrafish embryo as a 
model to determine the targeted organs of bacterial toxins.  Employing this 
model, this chapter investigates the in vivo targets of TcdB, the major cytotoxin of 
C. difficile.  TcdB is an example of a bacterial toxin whose in vivo targets are 
unknown, thereby limiting our knowledge of C. difficile pathogenesis.  CDAD is a 
complex disease that has, in recent years, become an increasing cause of 
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severe disease and death.  Although its other major toxin, TcdA, is known to be 
an enterotoxin, TcdB has very little enterotoxic activity and is a broad cytotoxin 
known to hit a variety of cell types.  Therefore, the organs targeted by TcdB 
during severe disease are unknown and, consequentially, TcdB’s role in CDAD is 
unidentified.  This gap makes it difficult to discern the cascade of events leading 
to the serious, systemic damage observed in fulminant disease and, more 
importantly, has hindered physicians’ ability to provide targeted and meaningful 
appropriate short and long term treatment regimen to CDAD patients.   
 
Prior to this work, TcdB was known only as a broad cytotoxin.  Using the 
zebrafish as a model, we determined the localization of TcdB and the phenotypic 
changes induced by TcdB.  From this information, we were then able to 
investigate the mechanism of organ damage via the disruption of cardiomyocyte 
physiology.  Also using the model we were able to test a potential toxin 
therapeutic.   
 
First, embryos were treated with fluorescently-labeled TcdB and observed for 
localization of toxin.  Approximately 24 hpt, punctuated sites of toxin were 
observed throughout the zebrafish body; however, the greatest accumulation of 
toxin was found within the pericardial region of treated zebrafish.  In order to 
determine whether this was a toxin specific event, zebrafish were treated with a 
30-fold molar excess of the receptor-binding domain of TcdB.  The receptor 
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binding domain was found to competitively prevent the localization of labeled 
TcdB, indicating that pericardial localization of toxin was a TcdB-specific event.    
 
To investigate the real-time impact of TcdB on the animal, zebrafish embryos 
were treated with toxin and changes in phenotype were observed.  The 
phenotype of intoxicated zebrafish was obvious; following intoxication, the 
animals developed pericardial edema that eventually resulted in whole-body 
edema.  Using a database of zebrafish mutants with established phenotypes, it 
was discovered that zebrafish with mutations in genes required for a functioning 
cardiovascular system exhibited a phenotype similar to that of the zebrafish 
treated with TcdB, thus prompting investigations into the effect of TcdB on the 
cardiovascular system.   
 
Because zebrafish are optically transparent, blood-flow of the animal can be 
observed via simple light microscopy.  Approximately 24 hpt with TcdB, there was 
a noticeable decline in the red blood cell (RBC) perfusion rate, which, over time, 
continued to decrease until flow rate ceased.  A possible explanation for this 
phenomenon is the destruction of vein integrity via TcdB; however, red blood 
cells were still capable of moving through blood vessels, albeit at a reduced rate.  
To further confirm vein integrity, transgenic zebrafish that expressed GFP within 
endothelial cells were used to assess the impact of TcdB on vein structure by 
observing any loss in ultrastructure or decrease in GFP expression.  Using this 
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approach, it was determined that TcdB caused no discernable loss in vein 
integrity.     
 
The heart was examined next as a possible source of a decrease in RBC 
perfusion rate.  Between 24 and 48 h following treatment with TcdB, there was a 
decrease in heart rate and loss in cardiac rhythmicity.  Furthermore, there was a 
noticeable decrease in ventricle chamber contractility, impeding the overall flow 
of blood through the heart and into the rest of the animal.  As damage was 
allowed to progressed, the heart underwent drastic changes in morphology and 
the tissue appeared necrotic.  Finally, the heart was unable to contract and 
subsequently blood flow ceased.   
 
In order to determine the mechanism by which TcdB caused cardiac damage, it 
was necessary to determine whether TcdB had a specific tropism for the heart or 
if cardiac tissue was simply more sensitive to inactivation of Rho, Rac, and 
Cdc42.  This was accomplished using a surrogate system to delivery TcdB into 
mammalian cells.  Briefly, the enzymatic domain of TcdB was fused to a 
truncated form of lethal factor that is translocation active but enzymatically 
inactive.  Therefore, the enzymatic region of TcdB was delivered into the cell 
using the anthrax toxin receptor, which is widely distributed throughout zebrafish 
tissue (197).  If cardiac tissue was more sensitive to the inactivation of Rho, Rac, 
and Cdc42, then the heart would be preferentially impacted despite localization 
of the enzymatic domain to multiple tissues.  However, if TcdB has a specific 
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tropism for the heart, then delivery of the TcdB enzymatic domain via the widely-
distributed anthrax toxin receptor would result in non-specific tissue damage.  
Using this surrogate delivery system, TcdB was found to cause widespread tissue 
degeneration, indicating that TcdB has a cardio-specific tropism, confirming the 
localization studies.   
 
To further determine the cause of cardiac damage by TcdB, the effect of TcdB on 
cardiac cell physiology was explored.  Cardiomyocytes are the functional cell of 
the heart and control the contraction and expansion of cardiac tissue.  Following 
intoxication, cardiomyocytes not only underwent changes in cell morphology but 
also in cell physiology, with a decrease in rhythmicity and coordinated 
contraction.  Loss in cardiomyocyte function could be a possible explanation for 
the decrease in heart rate, rhythmicity, and chamber contraction. Although 
cardiac fibroblasts could be targeted by TcdB as well, the loss in cardiomyocyte 
function would have the most drastic impact on heart physiology.  Overall, 
because of the zebrafish model, we were able to closely examine the effects of 
TcdB on a relevant cell-type, and found that the disruption of cardiomyocyte 
physiology may be a mechanism by which TcdB disrupts cardiac function.  
 
Overall, Chapter IV provides evidence that TcdB acts as a potent cardiotoxin.  
Not only does TcdB have specific tropism for the heart in zebrafish, but it also 
disrupts basic cardiac function.  Furthermore, TcdB drastically alters the 
physiology of cardiomyocytes, the functional cells of the heart.   These data 
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provides the first insight into the in vivo targets of TcdB and a possible role for 
this toxin in fulminant disease.  Finally, this chapter also introduces the zebrafish 
as a useful model for determining the in vivo targets of bacterial toxins.   
 
Using the zebrafish model of intoxication, the heart was identified as a target of 
TcdB, allowing for more focused examination into the causes of severe CDAD.  
Chapter V further describes the cardiac damage found in severe disease using 
both rodent and patient studies.   First, the systemic impact of TcdB on the heart 
was investigated using the murine model.  Mice were injected with lethal and 
sublethal doses of TcdB and then their organs were examined for damage.  
Administration of both lethal doses and sublethal injection of TcdB resulted in 
cardiac damage that included damage to myocardial cells and fibers, edema, 
hemorrhaging, and infiltration of lymphocytes, indicating that systemic 
intoxication with TcdB can result in massive myocardial infarct and cardiac tissue 
damage. 
        
In order to correlate the zebrafish and mouse toxin data to the systemic effects of 
a severe C. difficile infection, a C. difficile infection model was used.  Following 
treatment with clindamycin, hamsters were orally administered C. difficile and, 
upon disease-related death, pathology was performed on the collected organs.  
Similar to the TcdB intoxication models, hamsters with CDAD also exhibited 
damage to their hearts, including myocardial infarct, edema, hemorrhaging, 
damage to myocardial cells and fibers, as well as infiltration of lymphocytes.  
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Finally, patient autopsy reports were analyzed to determine whether patients who 
died with CDAD exhibited signs of cardiac damage.  In a preliminary study of 5 
autopsies, substantial damage to cardiac tissue was detected in all 5 cases.  
Although it remains unknown whether this damage was due to prior conditions or 
to severe CDAD, this initial analysis indicates that CDAD may contribute to heart 
damage.  Clearly, a more extensive panel of patients will be required for a full, 
comprehensive investigation into the heart damage in human CDAD; however, 
results from this initial study appear promising.   
 
Overall, the research herein presents not only a new animal model to study 
bacterial toxins but also a four-arm approach to pathogenesis disease research.  
Using a combination of tissue culture, zebrafish, rodent, and patient studies, we 
were able to gain meaningful, more inclusive insight into a complex and serious 
disease, C. difficile-associated disease.  Initial studies in zebrafish and in tissue 
culture indicate that TcdB has a specific tropism for cardiac tissue and disrupts 
cardiomyocyte physiology, ultimately resulting in damage to the heart and 
disruption of heart function.  Further studies revealed that a systemic TcdB 
intoxication event and severe C. difficile infection also caused heart damage. 
Using information for these studies, we were able to more closely examine the 
hearts of patients who died with CDAD.  In an initial, retrospective study, all five 
patients exhibited massive cardiac damage detected similar to that revealed in 
the rodent and zebrafish model.  Collectively, these data validate the robustness 
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of the developing zebrafish embryo as a model to study the in vivo activity and 
specific targets of bacterial toxins and further emphasizes the need to fully 
understand the systemic events and cardiotoxicity during CDAD.       
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